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Foreword

Dr Tedros Adhanom Ghebreyesus
Director-General
World Health Organization

Progress on the reduction and elimination of
HIV, viral hepatitis and sexually transmitted
infections looks very different now than it
did a year ago. Across the world, the COVID-19
pandemic has disrupted essential health services,
including those needed to support the prevention,
diagnoses, and treatment of these diseases.

Foreword

The 2021 global progress report on HIV, viral hepatitis
and sexually transmitted infections, is an opportunity to
take stock of the progress achieved in addressing these
diseases to date, the setbacks caused by the pandemic,
and the lessons learned for the coming decade.
This report documents the implementation of the
2016–2021 global health sector strategies for HIV, viral
hepatitis and sexually transmitted infections. Drawing
on data from multiple sources, it analyses progress and
highlights the continuing gaps. It reviews the activities
undertaken over the last five years against WHO’s five
strategic directions: information, services and essential
interventions, equity, financing and innovation.
There has been impressive progress in many areas
of the response, including the large-scale expansion
of HIV treatment, innovations in a cure for hepatitis
C virus, and increasing coverage of immunization for
hepatitis B virus and for human papillomavirus – the
latter a critical intervention to prevent cervical cancer.
Nevertheless, we are not on track to eliminate these
preventable and treatable diseases, which together
result in more than one million new infections every
day, and more than two million deaths and 1.2 million
new cases of cancer every year. In too many countries,
priority interventions remain inaccessible to the
populations most severely affected and at higher risk.

v

The COVID-19 pandemic has impeded the delivery
of core services that tackle HIV, viral hepatitis, and
sexually transmitted infections. During this incredibly
challenging year, we have witnessed the ability of
health and community systems to adapt to continue
to reach people in need. The lessons learned from the
innovations developed during the pandemic response
can inform core service delivery programming, as part
of the overall effort to achieve universal health coverage.
The report highlights the importance of peoplecentred services and the urgent need to focus on
inequalities and populations left behind: adolescent
girls and young women, their male partners, gay men
and other men who have sex with men, transgender
people, people who inject drugs, sex workers, people
in prisons and all vulnerable populations.
Our goal for the coming decade is to get back on track
by increasing the equitable delivery of services for
HIV, viral hepatitis and sexually transmitted infections
across the world. This report lays the groundwork for
the next phase of that work.
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Key messages
As the global health sector strategies
for HIV, viral hepatitis and sexually
transmitted infections (STIs)
2016–2021 near the end of their
implementation period, this report
provides accountability for the main
achievements and gaps to date and
highlights actions to take forward
towards eliminating these diseases
as public health threats by 2030.
The report publishes new estimates
for viral hepatitis with a threefold
improvement in the completeness
of reporting. It also publishes new
estimates for the main STIs, providing
a more accurate baseline to guide
priorities in the forthcoming decade.

Global messages
1.

HIV, viral hepatitis and sexually transmitted
infections (STIs) are major public health
threats worldwide. They account for more
than 2.3 million people dying per year,
which represents 14% of all deaths from
infectious and parasitic diseases, digestive
diseases and cancer. They also result in
more than 1 million people newly infected
each day and 1.2 million people developing
cancer each year. If we lose focus now, the
progress achieved so far will plateau with
the risk of resurgence. Time is running
short. To reach the 2030 targets, we need to
accelerate progress, address specific gaps
in implementation, and bring innovation to
scale across the three diseases.

2.

The epidemics and responses are
at different stages. This strategy
implementation period has seen tremendous
progress, including achievement of the
Sustainable Development Goals target to
reduce the incidence of hepatitis B virus.

• The global target of the Sustainable
Development Goals and the global health
sector strategy to reduce the incidence
of hepatitis B has been met, as measured
by the prevalence of hepatitis B surface
antigen to less than 1% by 2020 among
children younger than five years. Supported
by childhood immunization and prevention,
the reduction in the incidence of hepatitis
B infection is one of the few Sustainable
Development Goals health targets that is
on track to be achieved. Sustained and
regionally focused scale-up of the birth dose
of hepatitis B vaccine and of treatment of
the mother to prevent further hepatitis B
transmission are required to achieve impact
by 2030. In addition, there are massive
gaps in hepatitis B diagnosis and treatment,
including among the populations most
severely affected and at higher risk.
• New data show that 9.4 million people are
receiving treatment to cure chronic hepatitis
C virus infection, an almost 10-fold increase
from the baseline of 1 million at the end of
2015. This scale-up of treatment has been
sufficient to reverse the trend of increasing
mortality from hepatitis C for the first time.
In Egypt, universal access to treatment has
resulted in declining mortality and incidence.
However, improved data show that the
number of people dying from hepatitis B
and C worldwide still remains daunting at
1.1 million per year.

Key messages

• Seventy-three per cent of all people living
with HIV and 85% of pregnant women living
with HIV are receiving antiretroviral therapy
in 2020, supporting a substantial decline in
mortality related to HIV and AIDS. Treatment
coverage in sub-Saharan Africa is uniquely
higher than global coverage because of
sustained partner and country financing.
• The global response to STIs is gathering
momentum after years of neglect. More
countries have national strategic plans and
updated guidelines to address STIs, and
coverage of interventions such as syphilis
screening of pregnant women in antenatal
care and human papillomavirus vaccination,
are increasing.

3.

Yet many gaps remain. Most global 2020
targets have been missed, and accelerated
action is needed to reach the Sustainable
Development Goals in the next decade.

• With an estimated 1.5 million people acquiring
HIV in 2020, the number has fallen by 31% to
the lowest since 2010. However, this remains
far below the global target of less than 500
000 people newly infected by 2020. Ending
the global HIV epidemic will require stronger
commitment to address the inequalities,
stigma and discrimination that continue to
drive the epidemic and prevent many people
from accessing the services they need. This
was the focus of the United Nations High Level
meeting on HIV in June 2020.

• New data show that hepatitis B and C
cause 1.1 million deaths and 3.0 million
new infections per year. Only 10% of people
who have chronic infection with hepatitis
B virus are diagnosed, and 22% of which
receive treatment. For hepatitis C infection,
21% of people are diagnosed and 62% of
those diagnosed receive treatment. Price
reductions have made hepatitis C treatment
an affordable high-impact intervention, but
coverage needs to increase nearly sixfold in
the next decade to reach the 2030 targets
for elimination.
• New data on STIs show 374 million new
cases per year. Other than slow declines in
congenital syphilis, the incidence of most
other STIs is plateauing despite ambitious
targets. There is a major need to boost
synergistic efforts to prevent and treat STIs,
including HIV, among adolescent girls and
young women and key populations. Global
commitment, funding and an integrated
public health approach are essential to bend
the curve for these infections.
• Although an increasing number of countries
are organizing strategies and planning
frameworks across HIV, viral hepatitis
and STIs, most are missing important
opportunities to integrate and link services
and responses to provide people-centred
services that also leverage efficiency at the
primary health care and health system levels.
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4.

Stigma and inequalities facing the
populations most vulnerable and at risk
have to be addressed across all diseases to
reach the Sustainable Development Goals.
Key populations (including gay men and
other men who have sex with men, people
who inject drugs, sex workers, transgender
people and prisoners) and their partners
account for 62% of the people acquiring HIV.
Viral hepatitis disproportionately affects
those who are economically disadvantaged,
displaced people and migrants and rural
populations. Further, injecting drug use is a
major contributor to the number of people
newly infected with hepatitis C globally.
Many of these population groups overlap
with groups recognized as especially
vulnerable to STIs. Access to prevention,
harm reduction and health-care services
for these populations is largely insufficient,
and persistent stigma, inequalities,
criminalization and other sociostructural
barriers are preventing response efforts from
reaching the people who need them most.

5.

New WHO data show that HIV testing and
prevention, as well as Hepatitis B and C
services, are among the most frequently
disrupted services caused by COVID-19.
HIV treatment, as well as STI services have
also experienced disruption. The COVID-19
pandemic has forced all three disease
programmes to innovate to deliver and
maintain essential health services safely
within community-led, community-based and
differentiated models of care.
Making full use of such people-centred
and community-led innovations can
further enable countries to fully leverage
the capacity of health and community
systems and respond to the needs of the
most vulnerable people in an equitable and
sustainable manner.

6.

Regional differentiation in implementing
the strategies has amplified progress.
In the next stages, further granular and
differentiated approaches should be
developed by region, epidemic status and
population to ensure that targets are reached
in all settings and that no one is left behind.
Chapter 4 of this report present dedicated
regional messages.

Key messages

7.

Better data, greater focus on solutions to
address gaps in prevention, treatment and
delivery and renewed advocacy and demand
creation will be needed to reach the 2030
Sustainable Development Goal targets. This
report identifies 10 cross-cutting priority areas
that must be strengthened across HIV, viral
hepatitis and STIs to accelerate impact by 2030.
They cover actions updated since 2018 based on
successes and gaps for each of the five strategic
directions. They also include new actions that
align with the WHO Triple Billion targets to
address social and structural determinants of
these infections, promote joint management
across diseases and draws on lessons from the
COVID-19 pandemic to strengthen community
engagement and service delivery.

1. Leverage common people-centred and
disaggregated data platforms, including
strengthening digital health data and building
capacity to analyse and use data for improving
programmes.
2. Scale up point-of-care diagnostics, self-testing
and self-collection to reach everyone who is
vulnerable, at higher risk and hard to reach,
including key populations, infants and children
and men who are not engaged in care; continue
to simplify testing and treatment and improve
links so that those already diagnosed can
receive care rapidly.
3. Achieve triple elimination of mother-to-child
transmission of HIV, hepatitis B virus and
syphilis and explore the expansion of the
elimination focus to eliminating infection among
children for the next phase of the global health
sector strategies.

4. Improve access to drugs and diagnostics by
further reducing prices, including integrating
costs in national health and domestic financing.
5. Innovate to maximize the use of differentiated
and people-centred service delivery options
across HIV, viral hepatitis and STIs to tailor and
deliver services according to people’s needs
and preferences and train and empower more
health-care workers to provide treatment where
the availability of specialists is limited.
6. Innovate to strengthen community
engagement, community-based service
delivery and community-led monitoring in the
context of primary health care.
7. Protect against the threat of antimicrobial
resistance and other risks, including disruption
of services because of COVID-19 and other
global health emergencies.
8. Strengthen joint responses for HIV, viral
hepatitis and STIs with TB and other key
comorbidities by further aligning programme
management, service delivery and monitoring to
support universal health coverage.
9. Integrate sexual and reproductive health and
rights into existing programmes, raise the
profile of STIs and reinvigorate the emphasis on
primary prevention.
10. Address social and structural determinants
that impact vulnerability and access to
services and tackle the stigma, discrimination,
criminalization and inequalities that undermine
the response.
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The lessons from the COVID-19 response provide a
historical opportunity to foster greater solidarity and
innovation in the response to communicable diseases
over the next decade. Disease-specific responses
and the goals of universal health coverage and global
health security are mutually reinforcing and need to
be advanced together. By taking decisive action now,
we can prevent 2 million people from losing their lives
each year and emerge stronger from the challenge of
COVID-19 to reach the Sustainable Development Goals
by 2030.

The HIV responses of the health sector must be
strongly aligned with the Global AIDS Strategy 2021–
2026, developed by UNAIDS with support from WHO.
It also provides clear opportunities for synergy for
the responses focused on viral hepatitis and STIs.
The focus of the Global AIDS Strategy on addressing
inequalities to end AIDS as a public health threat
provides an important framework for all communicable
diseases alongside the Strategy’s three interlinked
priorities: maximizing equitable and equal access to
HIV services and solutions; breaking down barriers
to achieving HIV outcomes; and fully resourcing and
sustaining efficient HIV responses and integrating them
into systems for health, social protection, humanitarian
settings and pandemic responses.

Regional differentiation, progress and gaps
• The African Region leads the way in HIV testing
and treatment and has the opportunity over
the next decade to extend this to addressing
hepatitis B and C virus and to syphilis
transmission from mother to child in order
to dramatically reduce the high burden of
communicable diseases in the Region.
• The Region of the Americas has led approaches
to advance the triple elimination of mother-tochild transmission of HIV, hepatitis B and syphilis
and to deliver services along the cascade for key
populations. Over the next decade, they need to
systematically fill gaps in the HIV, viral hepatitis
and STI service cascades to leave no one behind.
• The South-East Asia Region has some of the
world’s leading programmes for key populations
and community-based responses. Three
countries in the Region have been validated for
EMTCT of HIV and syphilis and four countries
have been certified to have achieved hepatitis
B control through immunization. Progress in
the response to HIV and STIs has nevertheless
plateaued. Financing for HIV, viral hepatitis
and STIs needs to be sustained and expanded
towards universal health coverage.

• In the European Region, gaps in testing and
treatment for HIV, viral hepatitis and STIs need
to be filled rapidly. There have been major
advances in hepatitis programme planning, but
the estimated number of people acquiring HIV
has been increasing.
• The Eastern Mediterranean Region leads the way
in scaling up testing and treatment for hepatitis
C virus, accounting for 37% of the global total
number diagnosed and 52% of the global number
of people treated in 2019. Some countries have
an opportunity to move towards elimination. The
impact of these population-based approaches
needs to be expanded and transferred to ensure
that nobody is left behind in access to hepatitis B,
STIs and HIV services.
• The Western Pacific Region has made major
progress in expanding access to services for
hepatitis B and C virus, largely because of
domestic funding and substantial drug price
reductions. There is an opportunity to include viral
hepatitis, HIV and STIs in national health financing.

1

1
A backdrop of crisis,
resilience and innovation
HIV, viral hepatitis and sexually transmitted infections (STIs) account
for 2.3 million deaths per year, which represents 14% of deaths from
infectious and parasitic diseases, digestive diseases and cancer and
4% of deaths from all causes worldwide (1). They result in 1 million
people newly infected per day and 1.2 million people developing cancer
per year and continue to be a major public health burden in terms of
mortality, morbidity and quality of life. These communicable diseases
share common modes of transmission and determinants and call for
a common public health approach along the continuum of prevention,
diagnosis, treatment and care. Nevertheless, there are key differences
in their status in 2020, with important lessons to learn among these
diseases and joint opportunities to achieve universal health coverage.

1.2m
people develop cancer each
year due to viral hepatitis,
STIs and HIV

2
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In 2016, WHO Member States adopted three aligned global health
sector strategies on HIV, viral hepatitis and STIs, respectively,
to guide actions over the period 2016–2021 towards eliminating
them as public health threats by 2030. The strategies share a
common goal to progress towards universal health coverage,
a key priority of WHO’s Thirteenth General Programme of Work
2019–2023 and the 2030 Agenda for Sustainable Development
(2,3). The strategies are organized around a common framework
that promotes synergy across the diseases and with other
programmatic health priorities.
This is the second combined progress report on implementation
of these strategies, following the mid-term review of progress at
the end of 2018 (4). At the time, the pace of progress was uneven
and insufficient to meet global targets by 2030. The number of
people dying from HIV-related causes was declining with growing
access to treatment, but the number of people newly acquiring
HIV was not falling rapidly enough. The global response to
hepatitis B and C virus was gaining momentum, but access to
testing and treatment remained far below needs, and mortality
was increasing. The global response to STIs was in crisis after
years of neglect, highlighting an urgent need to revitalize STI
prevention. Key and vulnerable populations were not adequately
reached with essential interventions, and many opportunities for
joint action were being missed. The report called for accelerating
progress with integrated and people-centred approaches to end
the epidemics as public health threats by 2030.

Since the strategies are now in their final year of implementation,
this report takes stock of achievements and gaps, globally and by
region, at the end of 2020, and highlights action to take forward to
the new decade towards elimination by 2030. It also provides new
estimates on the disease burden of viral hepatitis and STIs, which
will enable a more informed global response as part of the next
phase of strategies for the period 2022–2030.
Further, this review comes at a critical moment when the
COVID-19 pandemic has placed an enormous strain on health
systems and financing worldwide and exposed their weaknesses
and inequalities. The report provides an opportunity to assess
the initial impact of COVID-19 and draw lessons from the global
response. The lessons from COVID-19 and the innovations
demonstrated by health and community systems to maintain
essential services during a crisis are highlighted throughout
the report.
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Table 1 presents the impact and service coverage targets of the
global health sector strategies for HIV, viral hepatitis and STIs
2016–2021 and provides an update on the achievement of these
targets by the end of 2020.

Table 1. Global health sector strategies for HIV, viral hepatitis and STIs 2016–2021:
targets and results

HIV
Impact
Targets (by 2020)

Status

• Reduce the annual number of people dying from HIV-related
causes to less than 500 000 globally by 2020

• 680 000 [480 000–1.0 million] people died from HIV-related causes
globally in 2020

• Reduce the number of people living with HIV dying from
tuberculosis (TB)-related causes by 75% by 2020

• 208 000 [177 000–242 000] people living with HIV died from
TB-related causes in 2019

• Reduce the number of people living with HIV dying from
hepatitis B– and C–related causes by 10%, in accordance with
the mortality targets for all people with chronic hepatitis B and
C infection

• No data

• Reduce the annual number of people acquiring HIV infection to
less than 500 000 by 2020

• 1.5 million [1.0 million–2.0 million] people acquired HIV infection in
2020

• Zero new infections among children (0–14 years old) by 2020

• 150 000 [100 000–240 000] children acquired HIV infection in 2020

Service coverage
• Ensure that 90% of people living with HIV know their HIV status

• 84% [67–>98%] of people living with HIV knew their HIV status
globally in 2020

• Ensure that 90% of the people who know their HIV-positive
status receive antiretroviral therapy

• 87% [67–>98%] of those who knew that they were HIV-positive were
accessing treatment in 2020

• Ensure that 90% of people living with HIV receiving treatment
have suppressed viral loads

• 90% [70–>98%] of people receiving treatment had suppressed viral
loads in 2020

Web Annex 1 provides a complete set of global and regional data and sources.
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Viral hepatitis
Impact
Targets (by 2020 and 2030)

Status

• 30% reduction in new cases of chronic viral hepatitis B and C
infections by 2020, 90% reduction by 2030

• 1.5 million [1.1 million–2.6 million] people were newly infected with
chronic hepatitis B infection in 2019

• 10% reduction in viral hepatitis B and C deaths by 2020, 65%
reduction by 2030

• 1.5 million [1.3 million–1.8 million] people were newly infected with
chronic hepatitis C infection in 2019
• 820 000 [450 000–950 000] people died from hepatitis B infection–
related causes in 2019
• 290 000 [230 000–580 000] people died from hepatitis C infection–
related causes in 2019

Service coverage
• 90% coverage of hepatitis B virus vaccine (third dose) by 2020

• 85% coverage of hepatitis B vaccine (third dose) in 2019

• 50% coverage of prevention of mother-to-child transmission of
hepatitis B virus by 2020, 90% coverage by 2030

• 43% global coverage for timely birth dose of hepatitis B vaccine
in 2019

• 95% of blood donations screened in a quality-assured manner
by 2020, 100% screened by 2030

• Only baseline data available: 97% of donations screened with
quality assurance in 2015

• 50% of injections administered with safety-engineered devices
in and out of health facilities by 2020, 90% by 2030

• 3.9% reuse of injection equipment in 2017

• 200 sterile needles and syringes provided per person who
injects drugs per year by 2020, 300 by 2030

• 33 syringes or needle sets per person who injects drugs per year
in 2017

• 30% of chronic viral hepatitis B and C infections diagnosed by
2020, 90% by 2030

• 30.4 million [24.3 million–38.0 million] people living with hepatitis B
knew their hepatitis B status in 2019

• 80% of eligible people with chronic hepatitis B and C virus
infection treated by 2030, respectively

• 6.6 million [5.3 million–8.3 million] people diagnosed with hepatitis B
received treatment in 2019
• 15.2 million [11.2 million–19.0 million] people living with hepatitis C
knew their hepatitis C status in 2019
• 9.4 million [7.5 million–11.7 million] people diagnosed with hepatitis C
infection had been treated using direct-acting antiviral drugs between
2015 and 2019

Web Annex 1 provides a complete set of global and regional data and sources.
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Sexually transmitted infections
Impact
Targets (by 2020 and 2030)

Status

•

90% reduction of Treponema pallidum incidence globally
(2018 global baseline)

•

7.1 million [2.4 million–11.5 million] people were newly infected
with T. pallidum in 2020

•

90% reduction in Neisseria gonorrhoeae incidence globally
(2018 global baseline)

•

82.4 million [47.7 million–130.4 million] people were newly
infected with N. gonorrhoeae in 2020

•

50 or fewer cases of congenital syphilis per 100 000 live
births in 80% of countries

•

473 [385–561] congenital syphilis cases per 100 000 live births in
2016, a decline of 12% in 4 years

•

Sustain 90% national coverage and at least 80% in every
district (or equivalent administrative unit) in countries with the
human papillomavirus vaccine in their national immunization
programme

•

Of 75 countries surveyed, 19 (25%) reported >80% human
papillomavirus vaccine coverage in 2019–2020

Service coverage, by 2020:
•

70% of countries have STI surveillance systems in place that
are able to monitor progress towards the relevant targets

•

97 of 110 countries (87%) had STI surveillance or monitoring in
place in 2019–2020

•

70% of countries have at least 95% of pregnant women
screened for HIV and/or syphilis; 95% of pregnant women
screened for HIV and/or syphilis with free, prior and informed
consent; 90% of pregnant women living with HIV receiving
effective treatment; and 95% of syphilis-seropositive pregnant
women treated with at least one dose of intramuscular
benzathine penicillin or other effective regimen

•

103 of 111 countries (93%) had policies for antenatal screening
and treatment of syphilis in 2019–2020

•

70% of key populations for HIV have access to a full range of
services relevant to STIs and HIV, including condoms

•

No data

•

70% of countries provide STI services or links to such services
in all primary, HIV, reproductive health, family planning and
antenatal and postnatal care services

•

Countries provided link to STI services in other health services,
such as primary health care (88%), HIV services (91%),
reproductive health services (84%), family planning (77%) and
pre- and postnatal services (89%) in 2019–2020

•

70% of countries deliver human papillomavirus (HPV)
vaccines through the national immunization programme

•

59% of countries included the HPV vaccine in the national
immunization schedule in 2019–2020

•

70% of countries report on antimicrobial resistance in N.
gonorrhoeae

•

64% of countries conducted surveillance of gonococcal
antimicrobial susceptibility in 2019–2020

Web Annex 1 provides a complete set of global and regional data and sources.
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Figure. 1 presents the accountability ratings for progress
achieved under each of the global health sector strategies,
towards impact and service coverage targets and towards
implementing the priority actions under each of the five
strategic directions of the strategies.

Fig. 1. Accountability for the global health sector strategies 2016–2021:
summary scorecard
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1.1 Major epidemics with
lessons across diseases
Together, HIV, viral hepatitis and
STIs form a cluster of interlinked
communicable diseases with
common determinants of health,
modes of transmission and high
rates of coinfection, especially
among populations most severely
affected and at higher risk.
This report publishes new estimates for hepatitis B and C
viruses and for the four main STIs, providing a more accurate
baseline for the forthcoming decade of progress towards
eliminating them by 2030.
Viral hepatitis accounts for a significant global disease burden
and high mortality from liver cancer and cirrhosis. In 2019,
296 million people were living with chronic hepatitis B virus
infection and 58 million people with chronic hepatitis C virus
infection worldwide. New estimates show that about 1.5 million
people newly acquire hepatitis B infection each year, despite
the availability of a highly efficacious vaccine. About 1.5 million
people newly acquire hepatitis C virus infection. Viral hepatitis
caused 1.1 million deaths in 2019, 96% of which were caused
by hepatitis B and C virus (5). Most of these deaths result from
chronic liver disease and liver cancer. The greatest burden
of hepatitis B and C infection is concentrated by geography
and population, with 80% of the global burden of hepatitis C
infection in the 10 most severely affected countries. People
from economically disadvantaged regions, displaced people
and migrants, and rural populations are more severely affected.
Further, injecting drug use is a major contributor to the hepatitis
C epidemic globally (6). Other affected population groups
include health-care workers exposed through needle-stick
injuries, people in prisons and closed settings, and gay men
and other men who have sex with men.
STIs are defined by multiple neglected pandemics that cause a
significant global disease burden. More than 1 million curable
STIs are acquired every day worldwide, primarily caused by
Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema
pallidum (syphilis) and Trichomonas vaginalis (7). This report
published new estimates for four curable STIs that indicate
a global incidence of 374 million new cases of these STIs,
including 128 million chlamydia cases; 82 million gonorrhoea

cases; 156 million trichomoniasis cases; and 7 million syphilis
cases each year. In addition, previous data indicate that more
than 1 in 7 women is estimated to have HPV infection, and
more than 500 million people have genital herpes simplex virus
(HSV) infection (8–10). Population groups that are especially
vulnerable to STIs include sex workers and their clients, gay
men and other men who have sex with men, transgender people,
young adults and adolescents, mobile populations and people
affected by conflict and civil unrest (11). A first systematic
review and meta-analysis of the global prevalence of syphilis
among gay men and other men who have sex with men found
that the global pooled prevalence from 2000 to 2020 was 7.5%
(12), and markedly higher than the 2020 estimate of 0.56%
for men in the general population. The global health sector
strategy focuses on three STIs that require immediate action for
control – N. gonorrhoeae infection, T. pallidum infection with the
elimination of congenital syphilis, and HPV infection.
An estimated 37.7 million people were living with HIV worldwide
in 2020. A total of 1.5 million people acquired HIV in 2020
alone, and 680 000 people died from HIV-related causes. Key
populations (including men who have sex with men, people who
inject drugs, sex workers, transgender people and prisoners)
and their partners accounted for 62% of the people newly
infected worldwide, including the largest share of people
acquiring HIV in nearly all regions (13). About 5500 adolescent
girls and young women (15-24 years old) acquire HIV each week,
and in sub-Saharan Africa, they are twice as likely to acquire
HIV as adolescent boys and young men (14). HIV is a major STI
and shares behavioural, social and structural determinants with
other STIs.

2.3m
More than 2.3 million
lives lost each year
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Fig. 2. Deaths related to HIV, viral hepatitis and STIs among all deaths related
to infectious and parasitic diseases, digestive diseases, and cancer, 2019

HIV
0.7 million

Total deaths caused by
infectious and parasitic
diseases, digestive
diseases, and cancer
16.9 million

Hepatitis B
0.8 million
Hepatitis C
0.3 million
HPV-related
cervical cancer
0.3 million
Syphilis
0.2 million

Other infectious and parasitic diseases,
digestive diseases, and cancer
14.5 million

HIV, hepatitis, and sexually
transmitted infections
2.3 million

86%

14%

Sources: Overall burden of disease: WHO Global Health Estimates [website] (1). HIV:
UNAIDS/WHO, 2020. Hepatitis: WHO, 2021. HPV-related cervical cancer: International
Agency for Research on Cancer and WHO, 2021. STIs: Korenromp et al. (15).
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Fig.3. New cases of four curable STIs among adults (15–49 years old)
per year, by sex, global, 2020
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Source: WHO, 2021.

Fig. 4. New cases of HIV, hepatitis B infection and hepatitis C virus
infection per year, by sex, global, 2019–2020
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Sources: HIV: UNAIDS/WHO, 2021. Hepatitis: WHO, 2021.

3.6m
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Table 2. New cancer cases attributable to HIV, viral hepatitis and STIs, 2018
Disease

New cases

Hepatocellular carcinoma caused by hepatitis B and C

500 000

Cervical cancer caused by HPV

570 000

Other types of cancer caused by viral hepatitis and HPV

140 000

Total

1 210 000

11

1.2m
new cancer cases
each year

Source: de Martel et al. (16).

Interlinked diseases with common
determinants and coinfections

Table 3. Coinfections and comorbidities related to HIV, viral hepatitis,
STIs and other major infectious diseases
Diseases

Summary of the evidence

HIV and viral hepatitis

2.7 million people are coinfected with HIV and hepatitis B virus (2015) (5).
2.3 million people are coinfected with HIV and hepatitis C virus (2015) (5).

HIV and viral hepatitis

Among people living with HIV, untreated hepatitis coinfection promotes more rapid
progression of hepatitis B– and/or C–related liver disease, hepatocellular cancer
and untimely death, undermining the gains of effective HIV treatment.
HIV coinfection doubles the risk of mother-to-child transmission of viral hepatitis (5).
More than half of all people coinfected with HIV and hepatitis C are people who
inject drugs.
Men living with HIV who have sex with men are at substantially higher risk of
hepatitis C infection (17).

HIV and all STIs

Both ulcerative and non-ulcerative STIs are associated with a several-fold increased
risk of transmitting or acquiring HIV (18).

HIV and HSV type 2 (HSV-2)

HSV-2 infection resulted in an estimated 420 000 [317 000–546 000] of the 1.4
million people 15–49 years old acquiring HIV through sexual transmission (2016) (8).

HIV and human papillomavirus (HPV)

HIV enhances HPV-induced carcinogenesis, and women living with HIV have a six-fold
risk of cervical cancer versus HIV-negative women (19).
28 000 [20 000–36 000] new cervical cancer cases are attributable to HIV infection
(2018) (19).

HIV and TB

208 000 [177 000–242 000] people living with HIV died in 2019 from HIV with TB as
a contributory cause of death.
815 000 [729 000–906 000] people living with HIV develop a new TB case (2019) (20).

HIV and COVID-19

Preliminary evidence suggests that people with HIV have increased risk of poor
outcomes with COVID-19 (21).

12

Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021

Diverse epidemics by WHO Region

Fig. 5. Number of people acquiring HIV and number of people dying
from HIV-related causes, 2020
GLOBAL
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WESTERN PACIFIC REGION
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from HIV-related causes:
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Source: UNAIDS/WHO, 2021.
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REGION

Number of people
acquiring HIV:
880 000
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Number of people dying
from HIV-related causes:
460 000
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Number of people
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from HIV-related causes:
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Number of people
acquiring HIV:
100 000
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Number of people dying
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82 000
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Fig. 6. Hepatitis B and C new infections and mortality by WHO region, 2019
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Fig. 7. Incident cases of four curable STIs among adults (15–49 years old),
by WHO region, 2020
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Fig. 8. Estimated age-standardized incidence of cervical cancer, all ages, 2020
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Sources: International Agency for Research on Cancer and WHO, 2021.
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Uneven distribution by population

Fig. 9. Prevalence of sexually transmitted infections among adults
(15–49 years old), by sex, by WHO region, 2020
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Fig. 10. Members of key populations acquiring HIV, global, 2020
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1.2 Disruption and opportunities
arising from COVID-19
Global efforts to eliminate HIV,
viral hepatitis and STIs required
acceleration to achieve targets even
before the COVID-19 pandemic. As
countries worldwide mobilized efforts
to mount a comprehensive public
health response to a new infectious
disease, the fact that global health
security would not be achieved
without resilient, adaptable and
equitable health systems to deliver
universal health coverage became
more evident than ever.

Essential health services began to resume by the second half
of 2020, but there is no room for complacency. Countries
have continued to face challenges as they faced new waves
of increasing COVID-19 transmission at the end of 2020.
Preliminary findings from the second round of the WHO pulse
survey conducted between December 2020 and March 2021
show that, despite evidence of resilience and innovation to
restore some services, disruption to essential health services is
still geographically widespread, and 94% of reporting countries
experienced some disruption. On average, 36% of countries
reported disruption to communicable disease services (31).

The response to the pandemic, with stay-at-home measures,
travel restrictions, physical distancing requirements and
supply chain interruptions, disrupted essential health services
in many places and threatened to halt or reverse the progress
achieved so far. In the first round of the WHO pulse survey
on the continuity of essential services during the COVID-19
pandemic conducted between May and September 2020,
nearly all the 105 reporting countries faced some disruption
of essential health services as a result of the pandemic (22).

This disruption results from a mix of supply- and demand-side
factors, and their extent can differ within a country in terms of
service delivery, population or geography. In some places, HIV
testing services, especially community and voluntary testing
activities, have been limited or restricted. Demand for services
has also declined as a result of physical distancing measures,
financial constraints or fear of contracting COVID-19. Some
countries now face the double challenge of mitigating the risk of
further disruption while having to catch up on disruption that has
already taken place. Ongoing efforts are needed to focus and
set priorities among interventions while planning for strategic
efforts to prevent going further off-track from achieving the
global goals.

Services for HIV, viral hepatitis and STIs were also affected.
In June 2020, 34 countries reported disruption in antiretroviral
therapy delivery. A study on how COVID-19 affected harmreduction services in seven countries in Asia found sudden
declines between April and June 2020 in needle and syringe
distribution and in HIV testing for people who inject drugs, with
some recovery from July 2020 onwards (23). The evidence on
how COVID-19 has affected reported STI cases is mixed. The data
available are mostly from high-income countries and suggest in
some places and among some populations that fewer STIs may
have been diagnosed in 2020 than in 2019 (24–30). This may
result from interruptions to STI testing services. Fully assessing
the impact of COVID requires generating additional clinical,
epidemiological and psychosocial data on the behavioural links
between COVID-19 and HIV, viral hepatitis and STIs.

HIV testing services and thus antiretroviral therapy initiation
have also continued to be affected in many countries. In the
second round of the WHO pulse survey, 49% of countries
reported some disruption to HIV testing and 46% to HIV
prevention. The number of countries showing disruption in
antiretroviral therapy delivery declined from 34 in June 2020
to 17 by March 2021, but one quarter of the reporting countries
continued to face disruption in newly initiating treatment.
Similarly, 43% of countries reported disruption in hepatitis B and
C diagnosis and treatment (31).
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Fig. 11. Percentages of countries reporting disruptions across tracer service
areas, January - March 2021
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Source: Second round of the national pulse survey on continuity of essential health
services during the COVID-19 pandemic: January–March 2021 (31).

Fig. 12. Number of countries reporting disruption in antiretroviral therapy
services in June 2020, November 2020 and March 2021
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Fig. 13. Disruption in other services for HIV and viral hepatitis, March 2021
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PULSE survey results only: in case of exclusion of “Not applicable” or “Do not know” responses in the denominator, the percentages of
countries reporting disruptions (i.e. ≥5%) are as follows: HIV testing services (49%), HIV prevention services (46%), Hepatitis B and C
diagnosis and treatment (43%), Initiation of new ARV treatment (25%) and Continuation of established ARV treatment (17%).
For more information on the PULSE survey: https://www.who.int/publications/i/item/WHO-2019-nCoV-EHS-continuity-survey-2021.1.

Sources: WHO HIV, hepatitis and sexually transmitted infections survey, 2021 and
Second round of the national pulse survey on continuity of essential health services
during the COVID-19 pandemic: January–March 2021 (31) (consolidated data).

Fig. 14. Disruption in antiretroviral therapy services caused by COVID-19 by WHO
region, March 2021
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Sources: WHO HIV, hepatitis and sexually transmitted infections survey, 2021 and
Second round of the national pulse survey on continuity of essential health services
during the COVID-19 pandemic: January–March 2021 (31) (consolidated data).
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Worldwide, countries and communities facing the COVID-19
pandemic have responded in innovative ways to adapt, combine,
differentiate, decentralize and simplify health services to meet
people’s needs during the crisis.
• Accelerating policy implementation. Many countries
worldwide were able to implement existing policies to provide
multimonth supplies of antiretroviral medicines to people
who did not have access to health facilities. This improved
patient security by ensuring continuity of HIV treatment
but also required adequate antiretroviral drug stocks. Other
programmes followed suit and provided opioid substitution
therapy and other treatments for multiple months (32).
• Leveraging health systems capacity. In sub-Saharan Africa,
countries used existing HIV and TB laboratory infrastructure,
sample transportation, quality assurance mechanisms and
staff to provide COVID-19 testing, although in some cases
this led to delays in testing for other diseases in the early
phase of the response (32).
• Simplifying community-based delivery. In the SouthEast Asia Region, countries shifted service delivery from
facilities to communities, providing take-home doses of
opioid substitution therapy to people who inject drugs, home
delivery of antiretroviral medicines for people unable to
reach facilities, delivering pre-exposure prophylaxis (PrEP)
through communities, introducing telehealth consultations
and training HIV teams, including virtually, on COVID-19
prevention and management (33,34).
• Developing strategies for safe delivery. In sub-Saharan
Africa, programmes delivering voluntary medical male
circumcision developed safer and more targeted mobilization
strategies. For example, in Uganda, a voluntary medical male
circumcision programme got back on track to meet its goals
by using strategies such as placing branded handwashing
stations in dense urban areas to support COVID-19
prevention efforts and emphasize that voluntary medical
male circumcision services remained available, restarting
outdoor-only, masked door-to-door mobilization, and
employing community educators to deliver both COVID-19
awareness and messages promoting voluntary medical male
circumcision (35).

21

• Expanding the use of self-care interventions. A project in
Bulgaria provided HIV self-testing and telemedicine to key
populations. Supported by a vast social media campaign
to disseminate information, the initiative helped to reach
men who have sex with men and transgender people with
HIV testing without having to visit a health facility (36). A
dedicated phone line was also available for follow-up. HIV
self-testing has also been expanded in many countries in the
African Region, Asia and the Americas.
• Increasing the use of digital health. In the Region of the
Americas, a project delivering PrEP to young key populations
in Brazil adapted its approach during the COVID-19 pandemic
by using telehealth, social media and an artificial intelligence
chatbot to recruit participants and provide information and
peer support. The team also provided discrete home delivery
of condoms, lubricants, self-tests for HIV and medicines for
PrEP (37).
The pandemic has demonstrated the importance and
effectiveness of making full use of such people-centred
and community-led solutions to deliver essential services
in an equitable and sustainable way. Maintaining these
innovative approaches as part of a catch-up of services can
enable countries to fully leverage the resilience of health
and community systems and respond to the needs of the
most vulnerable people in the path towards the Sustainable
Development Goals.
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Box 1.
HIV is a risk factor for illness severity among people hospitalized with
COVID-19
Preliminary analysis of clinical data of people hospitalized
with suspected or confirmed COVID-19 infection suggests
that HIV appears to be an independent risk factor for illness
severity and for in-hospital mortality.
The data submitted from 24 countries between January
2020 and March 2021 show that 46% (2638 of 5733) of
people living with HIV hospitalized with suspected or
confirmed COVID-19 had one or more underlying conditions
at admission. Eight per cent were reported to be coinfected
with TB (current or previous). Of the people living with
HIV who were hospitalized with suspected or confirmed
COVID-19 infection, 20% died during the hospital stay.

These data were collected as part of the WHO Global
COVID-19 Clinical Platform, a global initiative to expand the
understanding of clinical characteristics and prognostic
factors of people hospitalized with COVID-19 and to inform
optimal clinical management. Through a secure web-based
database, the initiative is collecting individual anonymized
clinical data for people hospitalized with suspected or
confirmed COVID-19 from health facilities worldwide (38).
WHO is continuing to expand the collection and analysis
of clinical data of people hospitalized with and without
HIV through the WHO Global COVID-19 Clinical Platform to
improve the understanding of the clinical characterization
and management impact of people hospitalized with
COVID-19.

Fig.15. Outcomes among people living with HIV hospitalised with COVID-19,
by severity of illness at hospital admission
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at hospital admission
621; 16%

Severe/critical illness
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Hospitalized cases from 35 countries submitted to WHO Global Clinical Platform for COVID-19 as of March 17, 2021.
N = 5810 of 67 372 (8.6%) with a recorded HIV status were reported as HIV positive.
90.8% (5275/5810) of the people living with HIV were reported from the WHO African Region.
Source: WHO, 2021.
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Box 2.
Methods and data sources
The information presented in this report is compiled from
several sources. The main sources and methods are
summarized below. Web Annex 2 provides full details.

• Yellow: incomplete, but major efforts underway.

Disease burden

Using the ratings published in the 2019 mid-term report as
a baseline, this report updates the ratings using the latest
available data as of the end of 2020. The method used in
the 2019 mid-term report is reapplied for these updates.
The actions are first scored individually, either by analysing
results against targets where quantifiable targets are
available or using information on the delivery of the priority
actions. Progress by strategic direction is then derived
by aggregating the individual scores. This report also
identifies priority actions to address underperforming areas.
Specifically, it focuses on actions that had not been achieved
at mid-term, assesses progress since then and documents
the corrective actions undertaken.

This report presents updated disease burden estimates for
viral hepatitis B and C and for the four main curable STIs
to account for the current status and provide a baseline for
the next strategy. Global estimates for viral hepatitis are
derived from global reporting, with a threefold increase from
42 in 2018 to 130 in 2019, in the completeness of reporting
compared with the previous report. Countries and partners
validated the data, to ensure updated data on disease burden
and on the diagnosis and treatment service cascade. Data
were validated for 130 countries representing 93% of the
disease burden and partner data (from the CDA Foundation,
Institute for Health Metrics and Evaluation, Imperial College,
University of Bristol and WHO) was validated by regions and
countries where there are gaps. For STIs, global and regional
estimates for chlamydia, gonorrhoea, trichomonas and
syphilis were derived using systematic reviews applying the
same methods as in 2012 (39) and 2016 (40).

Service coverage and policy uptake
HIV service coverage data have been obtained through
the Global AIDS Monitoring System validated by countries,
regions and globally. Data for viral hepatitis are derived from
the Global Reporting System for viral hepatitis, validated by
countries, regions and partners. Data on STIs are derived from
a WHO country survey on implementation of STI strategies
conducted in 2019 completed by 112 countries (41).

Impact of COVID-19
The data on HIV, viral hepatitis and STIs are complemented
by data from successive WHO pulse surveys on continuity
of essential health services during the COVID-19 pandemic,
conducted between May and September 2020 and December
2020 and March 2021. Further, detailed data were also
collected for HIV, viral hepatitis and STI service disruption.
Additional data on the impact of COVID-19 from global and
country-level partners and published literature are also used
where relevant.

Accountability scores
Each global health sector strategy defines fast-track priority
actions for implementation by countries and for WHO. To
assess progress achieved in implementing the global health
sector strategies, documented evidence for completion of
each action was reviewed to identify outstanding action and
explanations. Based on this review of the completion rate
of actions as defined in the strategies, each disease area
and strategic direction was rated using a five-point scale of
traffic-light colours:
• Dark green: on track, with minor gaps.
• Light green: on track, with few major gaps such as for
specific populations, locations or interventions.

• Orange: incomplete, with only minor efforts underway.
• Red: no progress.

Independent expert review
The report also draws on expert opinions from the WHO
Strategic and Technical Advisory Committee on HIV and
Viral Hepatitis (STAC-HIVHEP) and WHO partners working
on STIs. This external advisory group, comprised of expert
individuals from all WHO regions and key stakeholder
constituencies, provides independent strategic and technical
advice on WHO’s programme of work. At a meeting held at
the end of 2020, they reviewed achievements of the 2016–
2021 global health sector strategies and identified gaps to
address for developing the next strategies.

The data presented in this report have some
limitations
Although the global health sector strategies cover the period
2016–2021, it was considered important to conduct this
review at the start of the final implementation year to inform
the development of the new strategies during 2021 and
incorporate lessons learned from the COVID-19 pandemic.
The analysis of progress and gaps in this report therefore
primarily reflects data for 2019, collected during 2020 and
available by the first quarter of 2021. Updated data from
2021 have been used where available, in particular to reflect
the new disease burden estimates for viral hepatitis and STIs
and to incorporate the latest information on the impact of
COVID-19 on HIV, viral hepatitis and STI services. There has
been a considerable country, regional and partner effort to
improve the data in this report, especially for viral hepatitis
reporting, with completeness increasing from 42 to 130
countries. This provides a more reliable baseline on gaps
to fill during the next strategy, but confidence limits need to
be considered in interpreting trends over time because of
increased accuracy in the data. Using all available data, the
report provides a review of all impact and service delivery
targets in the strategies as well as the actions proposed at
the start of the strategy by strategic direction. In addition, it
includes a special focus on actions not achieved mid-term
and whether catch-up actions have been implemented.
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Box 3.
A country survey to assess the implementation of the global health sector
strategy for sexually transmitted infections 2016–2021
In 2019, WHO conducted a country survey among 194
Member States to assess progress towards the targets of
the global health sector strategy for sexually transmitted
infections 2016–2021 (41). The data collected through
this survey are presented in Table 1 and are also included
in other sections of this report as relevant. They will also
inform the development of the next phase of the strategy for
the period 2022–2030.
Specifically, the survey sought to assess the achievement
of the following 2020 milestones within the global STI
strategy: (1) countries with a STI surveillance system in
place; (2) countries with a national policy for universal
screening of pregnant women for syphilis; (3) countries
providing STI services or links to such services, (4) countries
reporting on antimicrobial resistance of N. gonorrhoeae;
(5) key populations with access to STI and HIV services;
and (6) and countries including HPV vaccination within
national immunization schedules. The survey also assessed
programme service delivery and captured technical
assistance needs in STI programming and surveillance.
Of the 194 Member States receiving the survey, 112
returned a complete response. Overall, among these,
64% reported having a national STI strategy, and a higher
percentage reported having an STI surveillance system
and providing STI services or links to such services in

all primary, HIV, reproductive health, family planning and
pre- and postnatal care services. Table 1 presents the
results by indicator. Although the data suggest promising
evidence that STI programming is being given priority in
many reporting countries, they also reflect many gaps. For
example, although STI surveillance systems may be in place,
they mostly reflect case reporting based on syndromic
diagnosis of the common STI clinical presentations. About
96% of countries reported that HIV and syphilis testing
was available for the general population, but far fewer
countries reported the availability of testing for chlamydia,
gonorrhoea, HPV and herpes. Although STI services may be
available, the coverage and quality of these services may
be lacking. The global strategy milestone target of 70% of
countries having the HPV vaccine in national immunization
schedules has not been met. Interpretation of all data must
also consider reporting rates and reporting bias towards
survey completion by countries with better-developed STI
programming.
The survey provides important information for future priority
setting and investments by countries, global stakeholders
and international donors to bring the response to STIs back
on track. Direct technical assistance was requested by 70%
of surveyed countries to strengthen the STI response and
will be needed to accelerate progress.

© John Rae
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Box 4.
External review of progress in implementing the global health
sector strategies
The STAC-HIVHEP meets biennially to provide the WHO Director-General with independent
strategic and technical advice on WHO’s programme of work on the two epidemics. In 2020,
the STAC-HIVHEP also addressed the STI epidemics. It comprises expert individuals from all
WHO regions and key stakeholder groups, as appointed by the WHO Director-General.
In October 2012, the STAC-HIVHEP reviewed the global health sector strategies on HIV, viral
hepatitis and STIs 2016–2021, focusing on elements to be highlighted in the forthcoming
2022–2030 strategies.
The global responses to the HIV, viral hepatitis and STI
epidemics are at different junctures.
Expanded access to HIV treatment has reduced the number
of people dying from HIV-related causes to 680 000 in 2020,
the lowest number since 1994, but prevention is progressing
much too slowly with 1.5 million people acquiring HIV
annually versus a target of less than 500 000. The 2020 HIV
targets were not reached, and equity and financing gaps in
the HIV response remain major concerns.
The incidence of viral hepatitis B and hepatitis C infection
appears to be declining with 3 million people newly
infected, especially for hepatitis B virus, with the 2020
targets of the Sustainable Development Goals being
reached, but massive testing and treatment scale-up are
needed to reduce unacceptably high mortality of 1.1 million
and reach the 2030 targets. There are major opportunities
to prevent both hepatitis B and hepatitis C virus infections
and to treat and cure hepatitis C virus infection.
Responses to the main STI epidemics are slowly gathering
pace, but STI prevention, screening and treatment services
are missing many of the estimated 374 million people who
are living with at least one of four major STIs (N. gonorrhoeae,
C. trachomatis, T. pallidum and T. vaginalis infection).
The STAC-HIVHEP strongly supported WHO’s commitment
to pursue elimination targets for all three health strategies.
Success, it said, requires stronger political will, adequate
financing and ensuring that programmes reach populations
at higher risk, including through stronger community
engagement and by upholding people’s right to health.
Greater health equity is a priority, and integration can be
used to greater effect. The STAC-HIVHEP also called on
WHO to support countries to use all options to reduce prices
for vaccines, diagnostics and drugs for preventing and
treating HIV, viral hepatitis and other STIs (and COVID-19).

Strengths
Proven prevention, diagnostic and treatment tools and
methods exist for all three epidemics, and a growing
number of countries are using them effectively. Strategic
information systems are improving, and differentiated
services are more common.
HIV. Strong testing and treatment programmes exist
in most countries, with 84% of people living with HIV
knowing their status, 87% of the people who knew their
HIV-positive status accessing treatment and 90% of
the people receiving treatment having suppressed viral
loads. Strategic information system facilitate fine-tuned
interventions and accountability, with 63% of countries
having one integrated information system. Although
not used widely enough, highly effective prevention
technologies and interventions exist, and the obstacles
to their use (such as legal and policy barriers, stigma
and discrimination and weak demand creation) are well
understood. Key populations need to be a focus to achieve
ending AIDS as a public health threat.
Viral hepatitis. Scaled-up vaccination has steeply reduced
the prevalence of hepatitis B virus infection among children
younger than five years (to 0.9% in 2019), although birthdose coverage has not increased sufficiently. Treatment
cures exist for hepatitis C virus and are being used
successfully (notably in Egypt, Georgia, Mongolia and
Pakistan), and the prices of treatments for hepatitis B
virus and hepatitis C virus (including generic direct-acting
antiviral drugs) have fallen steeply in many countries.
STIs. There is a renewed focus on STIs, with 88% of
countries having STI surveillance in place, progress in
eliminating the mother-to-child transmission of syphilis,
64% of countries conducting surveillance of antimicrobial
resistance and paying more attention to preventing cervical
cancer. There is a basis for a phased approach that builds
on existing priority STI interventions and can be expanded
to other priority STIs.
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Weaknesses
The COVID-19 pandemic caused widespread service
disruption and highlighted ongoing inequalities and
inequities in who is able to access, afford and use life-saving
services and medicines. Diagnostic and treatment gaps
persist, especially for key populations. Legal and policy
barriers still pose hindrances, and funding shortfalls are a
common problem.
HIV. Prevention programmes are not keeping pace, leading
to growing epidemics, especially among key populations.
Only 40% of countries have operational needle and syringe
programmes in the Eastern Mediterranean Region, the
European Region, the Region of the Americas and parts of
Asia. Adolescent girls and young women continue to be at
very high risk of infection in the African Region, and only 55%
of countries have prevention strategies addressing adolescent
girls and young women. Widespread use of combination
prevention interventions is lacking, and funding allocation
often does not sufficiently reflect epidemic priorities.
Viral hepatitis. Only a fraction of people living with hepatitis
B virus or hepatitis C virus infection are being diagnosed
and treated. Globally, only about 5 million people received
hepatitis C treatment in 2017 and about 4.5 million people
received hepatitis B treatment in 2016. The new estimates
bring us to 9.4 million people receiving hepatitis C treatment
achieving the 2020 targets, but this is still far from our
goal of 40 million to reach 2030 targets. Although a global
reporting system was set up in 2018, country reporting is still
limited and up-to-date data are lacking. Improved strategic
information is vital to mobilize funding, set priorities and
monitor and evaluate programmes.
STIs. Major gaps persist in the availability of diagnosis and
treatment for the four most common curable STIs, although
88% of countries have STI services as part of primary health
care. Programmes are generally underfunded, despite
high levels of STI morbidity and mortality, and data gaps
undermine advocacy, funding mobilization and scale-up.
The STAC-HIVHEP urged WHO to advocate for including
STI programmes in national health budgets and improving
STI literacy among planners and practitioners in HIV, viral
hepatitis and other health programmes.

Opportunities
There are opportunities to further integrate or link services
(such as screening for HIV, viral hepatitis, other STIs, diabetes,
hypertension etc.), strategic information systems (such as
with HIV-related systems), laboratory services and platforms.
But integration approaches should not sacrifice crucial
features of infection-specific responses (such as community
engagement and serving key populations). Stronger action
can be taken to remove social, structural and legal barriers.
Facility-based services and support systems can be made
more decentralized, people-centred and sustainable through
the widespread implementation of differentiated service
delivery models of care such as through pop-up clinics, online
consultations and teleconsultations, self-testing, multimonth
dispensing and providing take-home dosages, telemedicine
for treatment follow-up and retention, contact tracing via
mobile phone applications and sharing laboratory capacity.

HIV. Reinvigorated primary prevention will strongly influence
the course of the epidemic. Improved, disaggregated data
will enable financing, resources and interventions to be
aligned more effectively with epidemiological trends (and
use population and location approaches). Community-led
organizations can be involved more centrally in designing,
implementing and monitoring services.
Viral hepatitis. Highly effective prevention tools exist for all
five hepatitis viruses (including a hepatitis B virus vaccine),
and there is effective treatment for chronic hepatitis B and
hepatitis C virus infection. There are huge opportunities to
use comparatively inexpensive hepatitis B virus treatments
(such as tenofovir) more widely and to achieve further price
reductions for direct-acting antiviral drugs, especially in lowand middle-income countries. Links with noncommunicable
disease programmes can be extended (for example, with
cancer control and care or with diabetes screening, as in
Egypt) and diagnostics can be integrated (for example, via
multiplex platforms) with HIV, TB and other programmes.
Simplified testing, care and treatment delivery pathways will
enhance programmes.
STIs. Cost-effective interventions exist for the major
infections. Countries need to increase access to and
manage symptomatic STIs as a priority through appropriate
approaches. For example, STI screening and treatment of
key populations with prevention and PrEP programmes
and giving priority to pregnant women for eliminating
syphilis are examples of programme integration for STI
impact. Countries can move from syndromic management
to etiological diagnosis and management, simplify
programmes and focus on enhancing access to currently
available interventions though community testing, lay
provider testing, assisted partner notification and selfcollection for diagnosis and self-care approaches.

Threats
Funding gaps are expected to continue, especially in the
wake of the COVID-19 pandemic, and the responses to HIV,
viral hepatitis and STIs risk being overshadowed by other
public health and development priorities.
HIV. International donor funding has levelled off over the
past several years, and the political will to support priority
services for key and other marginalized populations is
faltering in several countries.
Viral hepatitis. Programmes are being held back by a lack
of funding and the high prices of diagnostics, treatments
and vaccines, especially in low- and middle-income
countries with a high viral hepatitis burden. The COVID-19
pandemic threatens the expansion of nascent viral hepatitis
programmes.
STIs. Programmes are underfunded despite high levels
of STI morbidity and mortality. Poor awareness about
the STIs epidemics and continued stigma could lead to
programmes being eclipsed by other priorities. A resurgence
of conservatism in many countries threatens STI and sexual
and reproductive health programmes.
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2
Progress
towards impact
There has been significant progress
in many areas during this strategy
implementation period, but most
global impact targets for 2020 have
been missed.
There has been solid progress against hepatitis B virus based on
prevention and increasing immunization rates. The 2020 targets
for viral hepatitis B prevention are on track, and the global target
of hepatitis B surface antigen prevalence of below 1% for 2020
among children younger than five years is one of the first 2020
targets of the health-related Sustainable Development Goals
to be met. However, progress in reducing the prevalence of
hepatitis B infection among children younger than five years is
not matched with equal progress in addressing hepatitis B and C
infection among adults. Further, although mortality from hepatitis
C is declining for the first time, supported by a 10-fold increase
in treatment for hepatitis C virus compared with the strategy
baseline, treatment coverage remains 13% (21% diagnosed and
62% treated) in relation to need. Treatment for hepatitis B is
progressing much too slowly despite affordable treatments, as
is hepatitis C prevention and harm reduction among people who
inject drugs.
The number of people acquiring HIV has not declined sufficiently
to achieve the Fast-Track commitments to end AIDS by 2030
as a public health threat. AIDS-related mortality had dropped
significantly, but an unacceptably high number of people still
die (42). The response to the major STIs is slowly gathering
pace after years of neglect, but other than declines in rates of
congenital syphilis, the rates of other infections have plateaued
or, in the worst situations, certain STIs may have increased during
the COVID-19 pandemic (41).

Most 2020 targets have been
missed. Getting back on track will
prevent 2 million people from
dying each year and prevent
1 million people from becoming
newly infected each day

Progress was already insufficient before the COVID-19 pandemic
further deterred progress in many countries, and a doubling of
progress was needed to achieve the Sustainable Development
Goal trajectory. The unprecedented global health crisis has been
a stark reminder that disease-specific action and universal health
coverage goals are mutually reinforcing and must be advanced
together through a people-centred public health approach.
At the end of 2020, the responses to HIV, viral hepatitis and
STIs were at very different stages of progress, and much can
be learned across implementation of the strategies to optimize
opportunities through primary health care as the critical platform
to ensure universal access to prevention, testing, treatment
and care over the next decade. Urgent and decisive action is
necessary now and over the next decade to sustain progress,
prevent resurgence and accelerate action to eliminate HIV, viral
hepatitis and STIs by 2030 as part of broader global health goals.
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Fig. 16. Global trends in people acquiring HIV and people dying from HIV-related causes,
1990–2020 and projections to 2030
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Fig. 17. Progress towards 90–90–90 and 95–95–95 targets of the HIV service cascade by
WHO region, 2020
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An estimated 1.5 million people newly acquired HIV in 2020,
the lowest annual number since 1990. HIV incidence rate has
declined by 39% over the past 10 years. However, progress
continues to lag substantially behind the global target of less
than 500 000 people acquiring HIV annually by 2020.

The number of adolescent girls and young women (15-24 years
old) acquiring HIV declined by 19% globally from 2015 to 2019.
However, with 280 000 people newly infected in this population
group, this is still far higher than the target of less than 100 000
by 2020.

There has been significant progress globally towards the global
Fast-Track 90–90–90 targets of the HIV testing, treatment and
viral suppression cascade by 2020. At the end of 2020, 84% of
people living with HIV knew their HIV status. Of the 37.7 million
people living with HIV, 27.5 million, or 73%, were receiving
antiretroviral therapy; a number that has more than tripled
since 2010. Around 66% of people living with HIV globally had
suppressed viral loads. Further, 85% of pregnant women are
receiving antiretroviral therapy.

Ongoing expansion of HIV treatment, particularly rapid in
eastern and southern Africa, has reduced global deaths
related to HIV to the lowest number since 1994. An estimated
680 000 people died from HIV-related causes (one third from
TB) in 2020, a 55% reduction over the past 20 years (20).
Nevertheless, progress falls short of the global target to
reduce these to less than 500 000 globally by 2020.

Nevertheless, progress has been uneven, and coverage among
key populations is low. Children are also not being adequately
reached, and the world has failed to diagnose and start
treatment for almost half the children living with HIV. During
2020, an estimated 150 000 children acquired HIV globally, far
from the global 2020 target of 20 000. Only 54% of children
(0–14 years old) were receiving antiretroviral therapy, a total of
920 000 versus a target of 1.4 million by 2020.

Ending the global HIV epidemic will require stronger
commitment to reach the global 2025 targets of providing
comprehensive HIV services to 95% of the people who need
them, reducing number of people newly infected with HIV to
fewer than 370 000 and number of people died from HIVrelated causes to fewer than 250 000. These ambitious but
achievable targets can only be achieved by addressing the
determinants, inequalities, stigma and discrimination that
continue to drive the epidemic and prevent millions from
accessing the services they need.
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Fig. 18. New hepatitis B and C infections and mortality, hepatitis B prevalence among children and
estimated cancer deaths attributable to hepatitis B
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Global targets aim to reduce the number of people newly
infected with hepatitis B and C virus by 30% by 2020 and 90% by
2030. New estimates for 2019 show that 1.5 million people were
newly infected with chronic hepatitis B infection and 1.5 million
with chronic hepatitis C infection.
The number of people developing new chronic infections from
hepatitis B has declined, supported by an increase in the coverage
of the highly effective hepatitis B vaccine among infants. Globally,
85% of all infants had received the recommended three doses
of the hepatitis B vaccine in 2019, up from only 30% in 2000,
and the global target of the Sustainable Development Goals and
the global health sector strategy to reduce hepatitis B surface
antigen prevalence to less than 1% among children younger than
five years by 2020 has been met. However major gaps remain in
some regions, including sub-Saharan Africa and South-East Asia.
The 10-fold scale up of hepatitis C treatment during the strategy
implementation period has led to a stabilization of mortality for
the first time, although the annual number of people acquiring
hepatitis C infection at 1.5 million and dying from this at 290 000
remain unacceptably high.
Global targets call for a 10% reduction in the numbers of people
dying from viral hepatitis B and C by 2020 and a 65% reduction
by 2030. New estimates show that 1.1 million people died from

viral hepatitis in 2019. A huge scale-up and simplification of
hepatitis diagnosis and treatment are required to achieve the
targets for reduced mortality by 2030.
The momentum to address viral hepatitis is growing. Only 17
countries had national hepatitis strategic plans in 2012, but
this had increased to 124 by 2019. However, progress in service
delivery has been insufficient. Only 21% of people living with
chronic hepatitis C infection know their status. 9.4 million
people chronically infected with hepatitis C virus were
cumulatively receiving treatment at the end of 2019, a 10-fold
increase from 1 million people receiving treatment at the end of
2015, yet treatment coverage is only 13% of the people in need.
For hepatitis B, only 10% of people living with chronic hepatitis
B infection are diagnosed, and 6.6 million (2.2% coverage) are
receiving treatment.
The availability of effective hepatitis B vaccines, treatment
for chronic hepatitis B infection and direct-acting antiviral
treatment cure for chronic hepatitis C infection offer great
potential for eliminating these diseases as public health
threats by 2030. A collective effort is needed to address gaps
in the coverage of testing and treatment of hepatitis B and C
and in harm-reduction services for people who inject drugs to
achieve global goals.

Fig. 19. Viral hepatitis service cascade by WHO region, 2019
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Fig. 20. Incidence of gonorrhoea and syphilis: progress towards 2030 targets
INCIDENCE OF GONORRHOEA AMONG 15–49 YEARS OLD:
2030 TARGET AND PROGRESS IN 2020
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The global health sector strategy calls for a 90% reduction
in the incidence of N. gonorrhoeae and T. pallidum (syphilis)
and elimination of congenital syphilis by 2030. It also calls for
sustaining 90% national coverage in countries with the HPV
vaccine in their national immunization programme. This target
was reinforced in 2020 with a World Health Assembly resolution,
calling on all countries, by 2030, to achieve 90% HPV vaccination
coverage, 70% screening coverage and 90% access to treatment
for cervical pre-cancer and cancer, including access to palliative
care (43).
The global response is off target. Other than slow declines
in congenital syphilis, the incidence of most other STIs has
plateaued (15). Congenital syphilis causes a wide range of
adverse birth outcomes, including 143 000 early fetal deaths
and stillbirths, 61 000 neonatal deaths and 41 000 preterm
or low-birth-weight births in 2016 (15). An estimated 604 000
women were diagnosed with cervical cancer, causing an
estimated 341 000 women to die in 2020. These infections
cause significant morbidity, including adverse birth outcomes
from vertical transmission, infertility and increased risk of
transmitting and acquiring HIV.

The global response to STIs is slowly gathering pace after
years of neglect. A WHO survey in 2019 found that, among
112 responding countries, 64% of countries had national STI
strategies and 87% had STI surveillance systems in place –
although data quality remains weak and most systems do not
adequately capture the causes of syndromes beyond syphilis.
About 90% of countries offer HIV and syphilis screening to all
pregnant women, and 59% had included the HPV vaccine in
national immunization schedules (41). As of November 2020,
WHO had validated 15 countries and territories as having
eliminated the mother-to-child transmission of HIV and/or
syphilis. Global commitment, funding and an integrated public
health approach will be essential to bend the curve for these
infections. Based on improved data in this report and actions
to strengthen surveillance, more granular and accurate targets
for viral hepatitis and STIs will be developed as part of the new
strategies, including interim targets for 2025.
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3
Progress by
strategic direction
This chapter accounts for progress achieved in
delivering the priority interventions and policies
of the global health sector strategies for HIV, viral
hepatitis and STIs. It highlights key achievements
and gaps and recommends priority actions to
advance progress towards global goals. The analysis
focuses on disease-specific actions as well as crosscutting priorities that can be addressed through
integrated efforts.

The three global health sector strategies are organized around
a common synergistic framework of five strategic directions to
advance progress towards universal access:
Information for focused action;

Interventions for impact;

Delivering for equity;

Financing for sustainability; and

Innovation for acceleration.
The sections below describe each of these further.

3. Progress by strategic direction

Fig. 21. The global health sector strategies for HIV, viral hepatitis and STIs 2016–2021:
a common universal health coverage framework

Source: Progress report on HIV, viral hepatitis and sexually transmitted infections 2019.
Accountability for the global health sector strategies, 2016–2021 (4).
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3.1
Information for
focused actions
Granular, person-centred data are a critical
pillar of primary health care and essential for
delivering people-centred health services. Data
are necessary to understand the epidemiological
context, focus efforts on the right interventions
and populations, tailor services to meet people’s
needs and bolster programme improvement. By
taking an integrated approach to strengthening
health information systems, countries have
a major opportunity to strengthen data
availability and quality across HIV, viral
hepatitis, STIs and other areas.

By moving beyond
aggregate measures,
person-centred data help
to deliver people-centred
health services that leave
no one behind.

3. Progress by strategic direction

This has helped to accelerate the achievement of key performance
indicators on health management information system data quality
from 22% to 43% of countries between 2018 and 2019, and data
disaggregation exceeds targets. The data summary work is now
being extended from the aggregate to the individual level and will
include data modules for STIs and viral hepatitis.

Data availability and use are improving. New global and regional
disease burden estimates are now available for viral hepatitis and
priority STIs, which will inform future investments. Nevertheless,
substantial gaps remain in the quality and scope of countrylevel surveillance systems for these infections. WHO has also
supported countries in implementing guidelines for personcentred data and electronic district-level health information
systems for HIV and worked closely with the Global Fund to Fight
AIDS, Tuberculosis and Malaria to promote district-level data use.

The availability of disaggregated data is also improving,
especially for HIV. The challenge is to ensure that all data
have sufficient granularity to explore the gaps in delivery and
inequalities in reach and are used to leave no one behind.

Fig. 22. A district-level data platform of standards and country applications implemented across
diseases and health
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GENERAL
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Source: WHO. Analysis and use of routine health facility data [website]. (44)

Fig. 23. The Data Initiative with the Global Fund and countries led to improvements in countries with
fully functioning health management information systems (HMIS) from 22% to 43% and in areas of
data timeliness and integration, 2018-2019
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Table 4. Information for focused action – global accountability 2020

HIV

Viral hepatitis

Sexually transmitted infections

There have been major advances in
people-centred monitoring over the
past five years, with increasing use
of individual-level data to identify
gaps and improve services. Patient
monitoring supports more than five
million people receiving treatment
in South Africa and large treatment
cohorts in many countries. As of
June 2020, 71% of countries had
updated their patient monitoring
systems with WHO person-centred
monitoring guidelines, and 73% of
countries used a national unique
identifier to link patient data.

Global reporting for viral hepatitis
has been established, and the
number of reporting countries has
increased from 42 in 2018 to 130
countries in 2019. Updated global
and regional estimates have been
developed in collaboration with
partners, including CDA Foundation,
Imperial College, the Institute for
Health Metrics and Evaluation and
the University of Bristol.

Updated STI global and regional
estimates for 2020 have been
developed, and 87% of countries
report having surveillance systems
in place, but the scope and quality
of these surveillance systems
remain critically weak.

Electronic district health information
systems have been strengthened
through collaboration of HIV, TB,
malaria and health programmes.

The first global costing of the
viral hepatitis response has been
developed showing a need of US$
6 billion per year and included in
the costing for universal health
coverage.

Digital health specifications have
been initiated for sexual and
reproductive health and HIV, which
support electronic reporting and
are being extended to additional
health areas. Data security
and confidentiality need to be
strengthened.

Improved granular generation, review and use of data are improving services using common health information platforms.
Gaps remain in surveillance systems and facility-level reporting for viral hepatitis and STIs.

PRIORITY
ACTIONS

• Strengthen country-level surveillance capacity for viral
hepatitis and STIs, with concerted investment in line with
the recommended 5–10% of programme funds invested
in strategic information for action.

• Take an integrated approach to strengthening data
availability and quality on the populations most severely
affected and at risk of infection, including population size
estimates and integrated biobehavioural surveys.

• Invest in person-centred data and monitoring, especially
for prevention, to link people at risk to services, retain
them in services and support them to remain negative.

• Joint efforts to strengthen routine data systems and use
data to improve health services and inform programme
priorities and design.

• Strengthen digital health data capacity, including
guidance on data interoperability and security.

• Use data to drive decision-making and ensure that no
one is left behind, including by strengthening communityled monitoring that is owned and used by programmes
working closely with the people who are most
marginalized and in need to improve access and quality
and holding service providers and decision-makers
accountable.

• Standardize analytical data reviews and build data
analysis capacity, especially at decentralized levels for
improving programmes.

3. Progress by strategic direction

Box 5.
Spotlight: using person-centred
data to measure people-centred
services

Box 6.
Extended person-centred data
for treatment and prevention
in Zimbabwe

Person-centred monitoring refers to monitoring that
places the individual at the centre of health service
delivery along the cascade of service provision. It involves
a shift away from measuring services at an aggregate
level towards supporting individuals as they are tested,
linked to treatment and retained at various service delivery
points. Such individual-level monitoring systems help to
deliver differentiated services, support long-term retention
in health care, optimize service delivery and improve
programme outcomes.

In Zimbabwe, successive population-based surveys
have shown declines in HIV prevalence larger than
many other countries in the African Region. In 2020,
the HIV prevalence among adults over 15 years old
was 12.9%, down from 18% in 2005. As Zimbabwe
works towards its national goal of achieving epidemic
control by 2030, it is expanding data analysis and use
to understand epidemic dynamics among various
population subgroups and geographical areas and tailor
local interventions accordingly.

In 2017, WHO published new consolidated guidelines
on person-centred HIV patient monitoring and case
surveillance (45). A total of 71% of countries have
updated their patient monitoring systems using these
guidelines, 73% of countries have national unique
person identifiers for patient data, and 92% of countries
have an HIV monitoring and evaluation plan in place.
The main areas of improvement include updating
patient monitoring tools to track patients as they move
across HIV services and facilities; expanding existing
HIV surveillance systems to adopt or strengthen HIV
case surveillance; transitioning from paper-based to
electronic information systems; and investing in human
resource capacity to analyse and use routine patient
data to inform programmes. Only 36% of countries have
systematic processes to monitor antiretroviral drug
toxicity and 47% to monitor HIV drug resistance.

Since 2017, Zimbabwe has applied WHO guidelines
to roll out an HIV patient monitoring and case-based
surveillance system that enables individual-level data
to be collected and used for improved patient care and
tracking over the patient’s lifetime (46). Implementation
began with a pilot phase in two districts during 2017–
2018. Using a combination of electronic and paper-based
systems, Zimbabwe is able to record sentinel events
along the cascade, including HIV diagnosis, enrolment in
care, follow-up, retention and viral load suppression.

Each country must determine the pace and pathway
for developing these systems in accordance with its
specific context, requirements and the availability of
human resources, financing and infrastructure capacity.
When planning for expanding person-centred monitoring,
countries should analyse the benefits and risks of
different approaches, in consultation with the affected
communities. In all cases, person-centred monitoring
must be based on strict protocols and procedures to
ensure data security and protect patient confidentiality.

An evaluation of the pilot in 2019 showed how weekly
analysis of data along the service cascade, conducted
at local levels with the support of community health
workers, is helping to identify and fill gaps and support
people living with HIV as they move between facilities.
The evaluation highlighted several findings that have
been useful for Zimbabwe as it plans a nationwide rollout of the system.
• Most stakeholders felt that the system was costeffective since it leveraged existing system capacity
and operations at the facility level.
• The pilot enabled health facilities to conduct simple
analysis of clients in their catchment areas and
helped to improve forecasting of antiretroviral
medicine requirements and minimize wastage.
• People living with HIV were supported as they moved
between facilities, allowing improved quality and
continuity of services.
• The use of unique patient identifiers based on
antiretroviral therapy was helpful since national IDs
were not always available, especially for adolescents
and non-Zimbabweans.
These lessons are also informing the expansion of
person-centred monitoring to HIV prevention services.
People received in HIV services who test negative but are
at risk are referred to prevention services. Person-centred
monitoring helps to assess whether they are retained in
these services and to follow up longitudinally to support
them to remain negative. Efforts are also underway to
extend the scope of the system, for example to include
STI data and when possible, data on hepatitis B and C.
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3.2
Interventions
for impact
The availability and quality of the essential
packages of health interventions have
improved significantly for all three disease
areas, but many gaps remain. Primary
prevention is lagging behind, especially the
prevention of HIV and STIs for populations
most severely affected and at higher risk.
Available diagnostics and treatment for viral
hepatitis and STIs are not accessible to many
people, and investment and political support
for harm-reduction services are critically
lacking in many regions. The response to STIs
has especially lagged behind as a result of
years of neglect and lack of resources.

Differentiated service
delivery options need
to be used optimally to
expand coverage and
respond to people’s
diverse needs and
preferences.

3. Progress by strategic direction

Recent evolutions in decentralized, simplified and integrated
service delivery models, further catalysed by the COVID-19
pandemic, are showing how existing health system resources
can be used more effectively to respond to people’s needs and
preferences. Such people-centred approaches need to be used
fully to accelerate progress over the next decade. A special
focus will be needed to recommit to address STIs through
more effective integration with HIV services and sexual and
reproductive health services more broadly.

Fig. 24. Hepatitis B birth dose vaccination strategies in the national immunization programme, April 2021

STATUS
HepB-BD introduced to date
HepB-BD only for infants born
to HBsAG-positive mothers
HepB in childhood schedule
but no universal HepB-BD
HepB only given to adolescents
or adult risk groups
No data
Not applicable

Source: WHO, 2021.
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Table 5. Interventions for impact – global accountability 2020

HIV

Viral hepatitis

Sexually transmitted infections

There have been strong gains
towards achieving the 90–90–90
targets by 2020 in many countries
with a high burden of HIV infection,
but progress varies by region and
population.

Access to infant hepatitis B
vaccination is high. Coverage of
three doses of hepatitis B infant
vaccination reached 85% worldwide,
although access to a timely birth
dose remains low in many African
countries, especially where antenatal
care coverage is low.

The country-level implementation
of WHO guidelines has improved
– 84% of surveyed countries use
WHO treatment guidelines for
STIs and 70% provide services or
links to HIV, reproductive health,
family planning, and prenatal and
postnatal services (41).

Pangenotypic direct-acting antiviral
drugs, effective against all six
genotypes of hepatitis C virus, are
available, providing an effective cure.
Coverage of hepatitis C treatment
has increased 10-fold since 2015
to 9.4 million people receiving
treatment; yet overall, only 10% of
people globally know their hepatitis
B status, and 21% for hepatitis C and
even fewer are receiving treatement.

The HPV vaccine is being rolled out
– 65 out of 110 countries have now
added the HPV vaccine into their
national immunization schedule;
however, coverage in low-income
countries is insufficient.

Differentiated approaches to service
delivery are improving prevention,
testing and treatment service reach
and quality.
As of June 2020, 78% of lowand middle-income countries
had carried out the transition
to dolutegravir as first-line
antiretroviral therapy.
The number of effective options
for HIV prevention, testing and
treatment is increasing, including
the dapivirine vaginal ring as
an additional prevention choice
for women; a new dispersible
strawberry-flavoured formulation
of dolutegravir for children; and
diversified testing approaches.

Some champion countries are
expanding access to hepatitis C
diagnosis and treatment through
public health approaches or
targeting microelimination in the
most affected subpopulations or
locations.

The WHO Model List of Essential
Medicines has been updated to
include new treatments for STIs.
There is increasing resistance
to azithromycin and emerging
resistance to ceftriaxone, last-line
treatment for N. gonorrhoeae.

Mother-to-child transmission of HIV and/or syphilis has been eliminated as a public health threat in 15 countries and
territories. As of June 2020, 82% of countries had a national plan for eliminating the mother-to-child transmission of HIV.
A dual HIV/syphilis rapid diagnostic test has been prequalified by WHO and used as the first test in antenatal care.

PRIORITY
ACTIONS

• Reinvigorate primary prevention, including condom use,
to prevent the sexual transmission of HIV and STIs, with
a focus on the populations most severely affected and at
higher risk of infection, and integration with sexual and
reproductive health services.
• Continue to differentiate and adapt service delivery by
making it more people-centred to meet the needs of
different population groups, bringing prevention, testing
and treatment closer to home and including leveraging
adaptations from the COVID-19 response.
• Expand, decentralize, integrate and simplify access to
diagnostics, so that services can be delivered at the
same site, with the use of affordable and quality rapid
diagnostic tests, including self-tests, serological and
molecular point-of-care and near-point of care tests, and
promote greater task sharing.

• Expand the provision of harm reduction in an integrated
and comprehensive manner.
• Make use of existing opportunities to accelerate the
triple elimination of mother-to-child transmission of
HIV, syphilis and hepatitis B virus through an integrated
approach that builds on a comprehensive antenatal
care platform that also incorporates eliminating cervical
cancer.
• Strengthen the response to antimicrobial drug resistance,
including through improved use of data to reduce loss to
follow-up.
• Integrate HIV, viral hepatitis and STI services within
a broader health systems approach, including with
noncommunicable diseases and cancer prevention and
care and primary health care initiatives.

3. Progress by strategic direction

Box 7.
Spotlight: applying differentiated service delivery to reach people better
Differentiated service delivery models apply a people-centred approach to simplify and adapt service provision to the
diverse needs and preferences of beneficiary populations. Since 2016, several countries have implemented various models
of differentiated service delivery as part of national policy, especially for delivering HIV treatment for adults established on
antiretroviral therapy, through approaches such as multimonth dispensing of medicines, client-managed groups for drug
pick-ups and peer support for adherence. Of 120 countries surveyed in 2019, 104 had adopted the WHO recommendation to
reduce the frequency of clinic visits and antiretroviral medicine refills for people established on treatment (48).
Fig. 25. Policy adoption of differentiated service delivery for HIV, 2020

DSD ADOPTION LEVEL
Not adopted
Partially adopted
Adopted
No data
Not applicable

Source: HIV Policy Lab, 2021.
Such differentiated models have been shown to improve
individual service uptake and outcomes, enhance service
quality and reduce unnecessary burden on a health system.
A rapid systematic review found that HIV treatment retention
in differentiated service delivery models exceeded 80%
and was similar to or better than conventional care (49).
Another review found that differentiated service delivery
of HIV treatment to people established on treatment saved
substantial money on travel costs and greatly reduced the
time required to receive treatment and modestly reduced
the use of health system resources (50). Differentiated
approaches are also being increasingly applied across the
cascade of services for HIV, including prevention, testing,
linkage to care, antiretroviral therapy and follow-up and
addressing HIV-related coinfections and comorbidities.
During the COVID-19 pandemic, many countries accelerated
and successfully applied the principles of differentiated
service delivery to ensure continued provision of essential
services to populations in need. For example, many
countries expanded the use of multimonth dispensing of
antiretroviral medicines for durations of 3–6 months to

reduce unnecessary contact with health facilities. Countries
also used community-based approaches to provide takehome doses of opioid substitution therapy and PrEP, expand
the use of HIV self-testing and use telehealth services for
peer support and care.
Although differentiated service delivery approaches have
mostly been applied to delivering long-term access to care
for people living with HIV, their basic principles – simplifying
and adapting services to the needs and preferences of
different groups – can also be applied to people with viral
hepatitis and STIs. For example, people with hepatitis C virus
infection can be broadly categorized into three groups –
those who are clinically well and stable, those with advanced
liver disease requiring more intensive clinical support and
those requiring additional psychosocial and mental health
support. Differentiated care models using facility-based,
community-based or mobile or outreach services can be
applied to tailor services to their specific needs. Making
full use of such differentiated approaches will be key to
delivering universal health coverage over the next decade.
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Box 8.
Differentiated service delivery during COVID-19 in Nigeria
When Nigeria introduced lockdown measures in early
2020 in response to the COVID-19 pandemic, it was able to
rapidly address disruptions in HIV treatment by leveraging
existing policies related to differentiated service delivery. In
2019, Nigeria had approved a national policy that enabled
multimonth dispensing of HIV medicines and using
community-based approaches to tailor and deliver services
to various groups of people living with HIV. The policy was
already in place in the 36 states and the Federal Capital
Territory; however, the benefit of such approaches became
more noticeable during the pandemic.

Faced with restrictions related to COVID-19, Nigeria was
able to improve communication and mobilize additional
community volunteers to deliver medicines to people’s
homes, especially in hard-to-reach semi-urban and rural
areas, and to provide adequate supplies to people that
would cover their needs for months. Services were provided
in partnership with community-based organizations,
including the Network of People Living with HIV/AIDS in
Nigeria. WHO supported the federal government through
the National AIDS and STIs Control Programme to ensure
the smooth functioning of differentiated service delivery
during the lockdown period. WHO also helped to develop
and disseminate guidance on the continuity of essential HIV
services in the context of a pandemic.

© John Rae

46

Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021

3.3
Delivering
for equity
The most marginalized, vulnerable and
underserved populations, who face the
highest rates of infection, often have the
poorest access to services. Persistent stigma,
inequalities, criminalization, violence and
other sociostructural barriers are preventing
response efforts from reaching the people and
communities who need them most.

To achieve impact, the
most vulnerable and
marginalized people
must be guaranteed their
right to health.

3. Progress by strategic direction

In addition, there are major gaps in reaching adolescent girls
and young women (15–24 years old) and children. With 280 000
adolescent girls and young women newly infected each year, this
is still far higher than the target of less than 100 000 by 2020.
Only 54% of children (0–14 years old) were receiving antiretroviral
therapy, a total of 920 000 versus a target of 1.4 million by 2020.
The gaps are most acute for key populations, such as men
who have sex with men, people who inject drugs, sex workers,
transgender people and people in prisons. Globally, these people
and their partners comprise an estimated 62% of the people
acquiring HIV and they have the highest risk of infection and

onward transmission in all regions. Some of these populations are
also disproportionately affected by viral hepatitis. More than half
the people who inject drugs have had hepatitis C virus infection
at some point in their lifetime. Modelled projections suggest
that eliminating the increased risk of hepatitis C transmission
among people who inject drugs would prevent about 40% of new
hepatitis C infections from 2018 to 2030 (51). Key populations
often have coinfections with STIs and viral hepatitis.
A rights-based and people-centred response, planned and
delivered with leading participation by affected populations,
will be essential to achieve true universal health coverage.

Fig. 26. Percentage of countries with operating harm-reduction programmes, 2019

Needle and syringe
program operational (n = 135)

Opioid substitution therapy
program operational (n = 134)
36%

33%
40%

64%

27%

Yes
No
No, but needles and syringes can be purchased
legally in pharmacies without a prescription

Source: Global AIDS Monitoring (UNAIDS/WHO/UNICEF), 2020.
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Table 6. Delivering for equity – global accountability 2020

HIV

Viral hepatitis

Sexually transmitted infections

Community-led interventions have
enabled major improvements
in service coverage for key
populations; yet gaps remain:
• one third of key populations did
not know their HIV status (52).

There are major gaps in hepatitis
B and C testing and treatment in
all populations, specifically among
economically disadvantaged
regions, rural and displaced
populations and key populations.

Rates of STI screening among key
populations are low compared with
HIV screening and highlight missed
opportunities to integrate STI
services with HIV and other health
services.

• only 44% of sex workers, 30% of
gay men and other men who have
sex with men and 34% of people
who inject drugs report having
received at least two prevention
services in the past three months
(13).

Community awareness and
advocacy related to viral hepatitis,
including eliminating hepatitis C
virus among people who inject
drugs, is increasing; however,
access to services remains low.

• Less than 50% of surveyed
countries provide STI testing for
key populations. Further, even
in countries that report having
integrated STI services in other
services such as family planning,
data are limited on actual STI
services provided in these
settings (41).

As of June 2020, 83% of countries
have a national plan or strategy
addressing gender-based violence
or violence against women that
includes HIV. However, there are
gaps in access to prevention and
support against gender-based
violence for women, gay men and
other men who have sex with men
and transgender people.

There have been major price
reductions in hepatitis diagnostics
and treatment (53) and yet many
middle-income countries are unable
to benefit from these prices as a
result of patent-related barriers.

More work is required across the three strategies to embed
community-led and community-based efforts across key
primary health care components, emphasizing integrated
services, community engagement and inclusive governance
and policy frameworks.
Adolescent girls and young women face particular
vulnerability for HIV and STIs related to gender-based
violence and harmful gender norms – two thirds of
adolescent girls and young women 15–24 years old in subSaharan Africa do not have comprehensive knowledge about
HIV (52). As of June 2020, 55% of countries have a national
prevention strategy to reduce the number of adolescent girls

Services need to be adopted and
scaled up to reach all partners,
including through social network
approaches, based on lessons
learned from HIV.

and young women and their male partners acquiring HIV in
communities with high HIV incidence.
Harm reduction coverage for people who inject drugs
remains low – 40% of countries report having operational
needle and syringe programmes, and 64% of countries
reported having operational opioid substitution therapy
programmes as of mid-2020.
There has been progress in decriminalizing behaviour such
as drug use, sex work and same-sex relations in some
countries, but several countries continue to have laws,
regulations or policies that are barriers to effective service.

PRIORITY
ACTIONS

• Design and deliver services that are people-centred and
decentralized in accordance with WHO’s operational
framework for primary health care (54), leveraging the
experience of HIV programmes and extending them
to a wider group of economically disadvantaged and
vulnerable populations; and engaging communities.
• Strengthen the focus on young people, including young
people from key populations.

• Expand the provision of prevention, harm reduction,
testing and treatment of HIV, viral hepatitis and STIs in an
integrated and comprehensive manner.
• Address stigma and discrimination, including within
health-care settings and by focusing on the health-care
workforce.
• Decriminalize behaviour such as drug use, sex work,
same-sex sexual relationships, sexual orientation and
nonconforming gender identities.

3. Progress by strategic direction

Box 9.
Spotlight: reforming policies and laws
Many of the populations who are most severely affected by HIV, viral hepatitis and STIs are also those that face the greatest
challenges in accessing necessary services. Gay men and other men who have sex with men, people in prisons and other
closed settings, people who inject drugs, sex workers and transgender people are confronted with social and structural
barriers that affect their health, safety and access to services. Their marginalization in turn influences epidemic dynamics
and diminishes the effectiveness of the response.
Repressive laws and policies are among the major threats to an effective response. More than 100 countries criminalize
some or all aspects of sex work, and at least 76 countries criminalize sexual relations between people of the same sex. Some
countries impose the death penalty for convictions under such laws (55). Several countries have adopted more punitive drug
strategies in 2020 compared with previous years (55).
Fig. 27 Percentage of countries with legal protection for sex workers, 2020

16%

Constitutional prohibition of
discrimination based on occupation

13%

Constitutional prohibition of
discrimination based on any grounds

2%

Sex work is recognized as work

3%
Other non-discrimination provisions
specifying sex work

66%

No

The total number of reporting countries is 127.
Source: Global AIDS Monitoring (UNAIDS/WHO/UNICEF), 2020.
Criminalization directly affects the health and safety of
these populations. A review of multiple studies found that
repressive policing practices of sex workers were associated
with increased risk of sexual or physical violence from
clients or other partners; and sex workers who had been
exposed to repressive policing practices had increased risk
of infection with HIV and STIs (56). In sub-Saharan Africa,
criminalization of same-sex sexual activity was consistently
associated with an increased risk of acquiring HIV among
gay men and other men who have sex with men. The HIV
prevalence among sampled gay men and other men who
have sex with men was as high as 52% in countries with
severe criminalization compared with 8% in countries with
no criminalization (57). Several countries have taken recent
steps to review and reform punitive laws and practices,
supported by advocacy and engagement by communities.

These efforts must be sustained, and all countries should
work towards decriminalizing behaviour such as drug use
and possession for personal use, sex work, same-sex sexual
relationships and sexual orientation and nonconforming
gender identities. They must strive to eliminate the unjust
application of civil law and regulations against people who
practice these types of behaviour to create equitable and
enabling environments for an effective public health response.
These approaches are relevant across HIV, viral hepatitis and
STIs, especially in relation to common determinants for sexual
behaviour for HIV and STIs and the role of unsafe injection
behaviour for HIV and viral hepatitis. The key and vulnerable
populations may vary but the interventions are synergistic.
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Box 10.
A western Africa strategy for the health of key populations,
free from stigma and discrimination
An estimated 5.1 million people are living with HIV in western
and central Africa, and most of the people acquiring HIV
are members of key populations and their partners. The HIV
prevalence in some key populations is as high as 34% versus
0.3–3.5% in the general population. The syphilis prevalence
among sex workers is estimated to be about 13% in the
African Region versus the overall median reported prevalence
of 3.2% – although data availability is limited.
Conservative cultural and gender norms, pervasive stigma
and discrimination and legal barriers continue to hinder
access to health services. Of 25 countries in western and
central Africa, 16 have laws that criminalize sex work,
12 criminalize same-sex relations with imprisonment up to
14 years and 21 retain the death penalty in law for people
convicted of drug-related offences (58). High levels of
population mobility, weak health infrastructure and instability
exacerbate the risks.

Recognizing the social and structural barriers faced by
key populations in accessing essential services and the
importance of addressing their needs through an integrated
public health approach, the Economic Community of West
Africa States (ECOWAS) adopted a Regional Strategy for HIV,
TB, Hepatitis B and C and Sexual and Reproductive Health
and Rights among Key Populations in 2020 (59).
This strategy for western Africa defines key populations as
gay men and other men who have sex with men; transgender
people; people who inject or use drugs; sex workers and
their clients; and people in prisons and other closed settings.
It aims to create an enabling legal, social and economic
environment in ECOWAS for universal health coverage for
these populations by strengthening national and regional
leadership and coordination, investing in data systems,
scaling up comprehensive service packages and ensuring
the meaningful participation of key populations in design,
implementation and monitoring. The strategy is guided by
human rights principles, community empowerment, evidenceinformed interventions and a commitment to accountability.

© John Rae
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3.4
Financing for
sustainability
More countries are demonstrating domestic
commitments to finance HIV, viral hepatitis
and STI services as part of their efforts to
progress towards universal health coverage.
Further, major declines in the prices of
medicines and other health commodities,
specifically for viral hepatitis and HIV, are
making a public health scale-up of diagnostics
and treatment more affordable. For a
sustainable response, global efforts at diseasespecific resource mobilization must continue
to be complemented by more integrated
approaches at country level to mobilize and
allocate resources efficiently through the
health system; and ensure that everyone can
receive services without incurring financial
hardship – thus attaining universal health
coverage as delivered through a primary care
framework. However, the macroeconomic
and fiscal implications of COVID-19 and the
response to it will affect domestic as well
as donor resources in the coming years,
increasing the challenge everywhere but
especially in low-income countries.

Integrated resource
planning and removing
price and regulatory
barriers will improve
access and efficiency.

3. Progress by strategic direction

Fig 28. Trends in drug prices for a) Lowest prices of direct-acting antiviral drugs
per 28-day supply b) ARV drug prices
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2016

2017

Tenofovir + lamivudine + evafirenz (TLE)
Tenofovir + lamivudine + dolutegravir (TLD)
Zidovudine + lamivudine + atazanavir/ritonavir (AZT+3TC+ATV/r)

2018

260
71 64
74
2019

Tenofovir + emtricitabine + efavirenz (TEE)
Zidovudine + lamivudine + lopinavir/ritonavir (AZT+3TC+LPV/r)
Darunavir/ritonavir (DRV/r)

Sources: a. Accelerating access to hepatitis C diagnostics and treatment: overcoming
barriers in low- and middle-income countries. Global progress report 2020 (53).
b. WHO Global Price Reporting Mechanism 2021.
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Table 7. Financing for sustainability – global accountability 2020

HIV

Viral hepatitis

Sexually transmitted infections

Substantial international funding,
but new commitments are declining
and the funding gap is increasing.

Resource needs and cost–
effectiveness data are available.
The first global costing of the
viral hepatitis response has been
developed, showing a need of US$
6 billion per year and included in
costing for universal health coverage;
however domestic and international
investments are lagging behind.

Large funding gaps and global neglect
of STI funding for many years.

The number of new HIV infections
needs to be reduced rapidly to
make the long-term costs of care
sustainable.

In the absence of a donor fund for
viral hepatitis, many countries that
have established a national viral
hepatitis programme have leveraged
domestic resources in the form of
either direct government budgetary
allocations to national programs or
via reimbursement through national
health insurance schemes.

Some progress in leveraging STI
management as part of HIV services
(such as in the case of PrEP) – but
overall limited success in leveraging
the increased funding for STIs as
part of HIV funding.
A low-cost rapid point-of-care test for
STIs is needed, including tests that
can diagnose multidrug-resistant
gonorrhoea and other resistant STIs.

There have been major declines in
drug prices for hepatitis C, expanding
access significantly.
Reductions in the prices of
diagnostics and simplification
of approaches provide major
opportunities for increased efficiency
in expanding testing.

PRIORITY
ACTIONS

• Maximize the use of available resources by using data to
focus resources on the populations and geographies with
greatest burden and lowest coverage.
• Continue to advocate for including medicines and
diagnostics for HIV, viral hepatitis and STIs within the
scope of publicly funded and guaranteed services as part
of government’s commitment to make progress towards
universal health coverage.
• Leverage task sharing as a pragmatic response
to address health worker shortages and expand
decentralized provision of testing, care and treatment,
especially for the hepatitis B and C response, to lowerlevel health facilities and using existing non-specialist
and primary health care workforce.

• Leverage efficiency in procurement and supply chain
mechanisms, including through improved joint analytics
and data sharing between patient and logistics data
systems.
• Leverage existing international financing opportunities
through partners such as the Global Fund and continue
to strengthen investment cases.

3. Progress by strategic direction

Box 11.
Spotlight: giving priority to eliminating viral hepatitis as part of
universal health coverage and primary health care
In 2019, WHO and partners developed the first comprehensive
global resource needs estimates for the hepatitis response
in the context of universal health coverage. The study found
that investing an additional US$ 58.7 billion over the period of
2016-2030, would avert 4.5 million premature deaths by 2030
and eliminate viral hepatitis as a public health threat in 67 lowand middle-income countries that account for the majority of
hepatitis B and C virus infections (60).
The rapid declines in the prices of commodities, supported
by increased competition from generic products, are making
this investment feasible for more countries. Low- and
middle-income countries can now aim to achieve a price as
low as US$ 60 per person for a 12-week course of hepatitis
C treatment with WHO-prequalified generic sofosbuvir and
daclatasvir (53). Countries have obtained similar reductions
in prices for hepatitis B commodities. For example, in China,
the cost for using tenofovir disoproxil fumarate to treat HIV
was US$ 240 per year through national procurement, whereas
the cost of tenofovir disoproxil fumarate from the originator
company to treat people with hepatitis B virus was US$ 2950
per year, mostly out of pocket. With the expiry of the global
patent for tenofovir disoproxil fumarate, central negotiations
and alignment with HIV pricing led to a reduction in the price
of tenofovir to US$ 30–35 per year by 2019 (61).
An increasing number of champion countries are giving
priority to financing and delivering viral hepatitis interventions
as part of national universal health coverage frameworks.
Supported by government commitment, updated national
strategic plans and simplified guidelines, countries are
making hepatitis treatment more widely available by

implementing a wide range of access strategies. Approaches
include expanding generic competition, addressing patentrelated barriers, conducting central price negotiations and
pooled procurement and ensuring timely product registration
and quality assurance processes.
However, many countries are not benefitting from these
prices, and great variation in prices and patent barriers
continue to persist among countries. In particular, high
prices in upper-middle-income countries because of patents
remain a major barrier to scale-up. For example, in 2019,
the lowest generic price for sofosbuvir was US$ 15 per 28day supply in India for a WHO-prequalified product. In the
Russian Federation, which is not included in the voluntary
licensing agreement with the originator company, the price
of sofosbuvir was US$ 1099 per 28-day supply. Expanding
access to simple, affordable and quality-assured hepatitis
C diagnostics is also urgently needed so that countries can
screen large numbers of people, identify people who need
treatment and provide appropriate care.
Continuing to pursue various strategies to reduce prices
will be essential to make hepatitis services more widely
available to everyone in need. Further, investing in scaling up
hepatitis diagnostics and treatment will also bring longerterm returns and remove an avoidable strain on the health
system. A hepatitis C virus transmission modelling exercise in
Pakistan projected that the health system would recover the
investment in elimination through savings in health-care costs
from prevented cases of cirrhosis and liver cancer in less than
three years (62).
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Box 12.
Domestic financing for hepatitis C treatment
in the Western Pacific Region
Of the 354 million people living with hepatitis B or hepatitis C virus globally, 35% live in the WHO Western Pacific Region. The
Region also accounts for 50% of the world’s new cases of liver cancer and associated deaths. Several countries in the region
are now including the costs of hepatitis commodities in government financing and/or national health insurance coverage.
Table 8. Hepatitis treatment financing in the WHO Western Pacific Region, November 2020

Country

Hepatitis B

Hepatitis C, direct-acting drugs

Australia

Financed

Financed

Brunei Darussalam

Financed

Financed

Cambodia

Out of pocket

Out of pocket

China

Financed

Financeda

China, Hong Kong SAR

Financed

Financed

China, Macao SAR

Financed

Financed

Japan

Financed

Financed

Lao People’s Democratic Republic

Out of pocket

Out of pocket

Malaysia

Financed

Financed

Mongolia

Financed

Financed

New Zealand

Financed

Financed

Papua New Guinea

Out of pocket

Out of pocketb

Philippines

c

Out of pocketc

Republic of Korea

Financed

Financed

Singapore

Financed

Financed

Viet Nam

Financed

Financed

China: direct-acting drugs under health reimbursements from January 2020.
Papua New Guinea: pilot employer private-public partnership model, Oro province.
c
Philippines: pilots for hepatitis B and C testing and treatment started with government financing in 2018, with hepatitis B
national expansion in April 2020.
a

b

Donor
supported

Pacific countries: hepatitis B treatment supported by a donor with transition to government financing:
Fiji, Kiribati, Solomon Islands, Tonga and Vanuatu.

Countries with hepatitis drugs financed

2014

2018

2020

6(all high income)

13

19(including countries with pilots)
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3.5
Innovation for
acceleration
Innovations with cross-cutting relevance
can catalyse the overcoming of barriers and
move the response to HIV, viral hepatitis and
STIs closer to the strategy targets. Ongoing
research in basic science, new tools and
technologies and service delivery approaches
is critical to enhance the efficiency, quality
and impact of the response. In addition,
innovative methods are needed to tackle
social and structural determinants related
to the three disease areas to ensure that
prevention efforts do not stall. Wider
diffusion of innovation is necessary to bring
successful approaches to scale to achieve
public health impact.

The potential of
innovative approaches
must be fully leveraged
and brought to scale
to achieve wider public
health impact

3. Progress by strategic direction

Fig. 29. Implementation of HIV self-testing by WHO region, 2020
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Table 9. Innovation for acceleration – global accountability 2020

HIV

Viral hepatitis

Sexually transmitted infections

The HIV response has strongly
focused on innovation in
technologies and service delivery
models.

Progressive simplification in
diagnostics and treatment
algorithms and service delivery
models for hepatitis C virus.

Expanded use of self-management
approaches such as self-sampling
for STIs.

Increasing options for HIV
prevention and treatment, including
the dapivirine vaginal ring as an
additional prevention choice for
women and a new dispersible
strawberry-flavoured formulation of
dolutegravir for children.

Progress in obtaining a cure for
hepatitis B is required to achieve the
2030 strategy targets.

Other innovations are in the pipeline
– related to long-lasting treatment,
prevention technologies and the
use of person-centred data, unique
identifiers to support people as they
move between facilities and digital
health tools to improve utilization of
appointments and services.

Implementation innovations to
simplify diagnostics and their
delivery and access are needed
as part of primary health care
approaches. Innovation needs
further development and quality
products including core antigen
for hepatitis C virus as a rapid
diagnostic test but even simply
having high-quality hepatitis B
surface antigen tests.

HIV mRNA vaccines are once again
showing promise, in part because
of extensive research to develop
vaccines for COVID-19.

Various new products in progress:
• Prequalification of diagnostic
tests for N. gonorrhoea and rapid
syphilis testing.
• New treatments for gonorrhoea
to address antimicrobial
resistance.
• Alternative treatments for
maternal syphilis.
• Promising vaccines against
gonorrhoea.
Innovation in service delivery
models is needed to integrate STI
testing into existing diagnostic
platforms and the provision of
integrated services.
Innovation is needed to address
social and structural determinants
relevant for preventing STIs and HIV.

Strong focus on cross-cutting innovations, such as differentiated and community-led models – accelerated during COVID-19.
Availability of new technologies to scale up diagnostics, such as triple HIV, syphilis and hepatitis B tests; point-of-care nucleic
acid tests for hepatitis B and C virus; and self-testing for hepatitis B, hepatitis C and STIs.
Greater use of virtual platforms and digital tools, especially to reach young people.

PRIORITY
ACTIONS

• Leverage the potential of innovative service delivery
approaches, including through self-management and
care approaches and community-led delivery, building on
lessons learned from the COVID-19 response.
• Leverage the potential of digital tools, including for
demand creation, service delivery and monitoring and
evaluation.

• Ensure continued investment in research in priority areas
– such as vaccines for HIV, hepatitis C virus, gonorrhoea
and HSV and a functional cure for hepatitis B.
• Seek opportunities for innovative approaches to address
the social determinants of health.

3. Progress by strategic direction

Box 13.
Spotlight: advancing community engagement and community-led
service delivery
In response to the COVID-19 pandemic, community-based
organizations worldwide stepped up efforts to identify and
expand innovative ways to continue to reach people with
essential services in contexts of lockdowns and stay-home
measures, physical distancing requirements, difficulties in
accessing health-care services and supply disruptions. As
highlighted in section 1.2, community-based organizations
delivered essential supplies such as antiretroviral therapy
and harm-reduction services directly within communities
and to people’s homes, expanded the use of self-testing
and self-management approaches and used telehealth
and social media to provide information and support, often
integrating COVID-19 messaging in their work.
Several of these approaches were already being successfully
used before the COVID-19 pandemic. Their expanded use in
the context of a public health crisis has clearly demonstrated
how community engagement plays a major role in delivering
people-centred services to populations that are hard to
reach. Community-based and peer-led approaches bring
services closer to people in need and deliver them in an
environment of trust. They empower individuals with a wider
choice of interventions, including greater possibilities for
self-care and autonomy. They also empower communities
to play a lead role in advocacy, priority-setting and designing
services to meet their needs and promote accountability.
Community-led service delivery is integral to effective
primary health care and an essential complement to
facility-based services. The health sector is transforming
rapidly with an increasing number of new diagnostics,
devices, medicines and other technologies that can be
self-administered and self-managed, often supported by

digital innovations. Community-based organizations and
community workers support the delivery of these new
technologies as a means to expand primary health care
beyond traditional delivery models and enable more people
to realize their right to health.
Young people in particular have emerged as critical
gatekeepers in pioneering and sustaining communityled innovations and should be further supported in
consolidating their leadership into the next phase of work
to reset the responses to HIV, hepatitis and STIs back on
track. In Manipur, India, young people are working with
mental health professionals to provide psychosocial support
and information for young transgender people during
the pandemic. In Zimbabwe, community adolescent HIV
treatment supporters provided information, referrals and
support to their peers using mobile phones (63).
The innovations introduced during the COVID-19 pandemic
must be sustained and leveraged to reach larger numbers
of the people most severely affected and at higher risk – to
achieve the goals of eliminating HIV, viral hepatitis and other
STIs as public health threats by 2030. Community-led and
community-based responses require greater investment
with stronger links to primary health care and its focus on
building people-centred, resilient and sustainable health
systems that uphold the right to health, promote social
justice, empower individuals and communities and address
the determinants of health. Countries are encouraged to
further scale up innovative community-led approaches
as they strive towards elimination, in accordance with
the pathways described in the WHO/UNICEF operational
framework for primary health care (54).
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Box 14.
Exploring the potential of digital
health to reach young people in
South Africa

Box 15.
Self-sampling for STIs to
maintain services for key
populations in Thailand

Young people in southern Africa have a high prevalence
of STIs but poor knowledge of STIs and of available
prevention and health-care services. Young people also
report concerns around confidentiality, provider attitudes
and feelings of stigma and shame as barriers to accessing
services (64).

Thailand faces a high burden of STIs among gay men and
other men who have sex with men and among transgender
women. In the first half of 2019, the COVID-19 pandemic
resulted in a decline of 50–75% in clients testing for HIV
and STIs in major HIV and STI service delivery centres.

Faced with COVID-19, a project providing sexual and
reproductive health services to adolescent girls and young
women 15–24 years old in South Africa rapidly adapted
its service delivery to the COVID-19 context (65). By using
social media, chatbots and messaging apps, the project
ensured that young people continued to have access to
information and education materials in times of lockdown.
The project decentralized service delivery to mobile
clinics and community delivery points and expanded
the use of telehealth for screening, consultations
and psychosocial support. They also sent electronic
prescriptions and postal self-testing or self-sampling kits
for HIV, chlamydia, syphilis and gonorrhoea, with follow-up
through telemedicine.
The project found that young clients responded positively
to having a wider choice of service delivery options for
sample collection, diagnosis, receiving results, initiating
treatment and notifying partners. It also found high
utilization of social media for information, screening and
follow-up, demonstrating the potential to extend these
adaptations in the future.

To maintain access to sexual health services while
respecting physical distancing and occupational safety
regulations, Thailand’s key population–led health services
programme introduced self-sampling for STIs at major
key population-led health clinics for the first time. Uptake
of self-sampling was high, and the rate of acceptance of
STI self-sampling increased from 48% in May 2020 to 78%
by July 2020. Thailand also adapted other services to the
COVID-19 context, such as extending PrEP prescriptions
from three to six months for continuing clients, delivering
medication and supplies discretely and using telehealth
consultations.
Such adaptations provide greater accessibility and
acceptability of services for populations in need and can
be sustainable over the long-term. A meta-analysis of
data from 11 studies from different countries found that
self-collection of samples nearly tripled the overall uptake
of STI testing services compared with clinician-based
collection, offering an important additional strategy to
increase service uptake (66).
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3.6 Cross-cutting actions
Joint action can create synergy across
health and community systems to
ensure the widest possible access
to high-quality services for all
populations in need and advance the
goals of universal health coverage.
This section accounts for the status
of cross-cutting priorities that were
identified in the mid-term review in
2018, identifies additional priorities
by drawing on lessons from the
COVID-19 response and provides a
view forward to 2030.

The public health
response to HIV, viral
hepatitis and STIs offers
many opportunities to
join forces to accelerate
towards achieving the
2030 elimination targets.

Table 10. Cross-cutting priority actions for the next decade
Priorities

Status in 2020

Catch-up actions to 2030

Actions identified in the mid-term review (2019)
1. Leverage common
disaggregated data
platforms

Electronic district-level data systems have been
implemented in most countries, with regular
data review to improve programmes. However,
gaps remain in facility-level reporting for viral
hepatitis and STIs and in the security and
interoperability of data systems.

•

Strengthen digital health data, including guidance on data
interoperability, security and unique identifiers.

•

Conduct standardized analytical reviews and build
capacity to use data at decentralized levels to improve
programmes.

•

Consider agile, small-scale surveys across the three
disease areas that can assess trends and progress in
specific populations.

2. Scale up pointof-care diagnostics
and self-testing

The availability of diagnostics for HIV, viral
hepatitis and STIs is improving, supported by
recent innovations. However, there are many
missed opportunities to leverage common
platforms for service delivery and common
learnings, such as in the case of self-testing
across all three disease areas.

•

Make self-testing available for all three disease areas,
especially to reach key and vulnerable populations and men.

•

Strengthen joint diagnostic platforms that can be
leveraged across all three disease areas and more widely
across health.

3. Achieve triple
elimination of
mother-to-child
transmission of HIV,
hepatitis B virus and
syphilis and explore
extending the
elimination focus to
children

There has been major progress in aligning
guidelines and processes and validating the first
set of countries for dual and triple elimination.
Fifteen countries have already been validated
as having eliminated the mother-to-child
transmission of HIV and/or syphilis as public
health threats, and two additional countries are
preparing to submit country data to join the path
towards elimination. Stronger incentives to align
countries in the full path towards elimination
would strengthen the approach, together with
further inclusion of hepatitis B.

•

Strengthen approaches and incentives to involve
countries in the full path towards elimination, including in
larger countries with a higher burden of disease.

•

Scale up the triple elimination of mother-to-child
transmission and, where feasible, expand approaches to
validate adult elimination, such as for hepatitis C virus
infection.

•

Develop strategies to expand the focus on eliminating
vertical transmission to eliminating infections among
children across the diseases.
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Priorities

Status in 2020

Catch-up actions to 2030

4. Improve access
to drugs and
diagnostics

The price reductions have been remarkable
for hepatitis C medicines in the past three
years and HIV over the last two decades.
These need to be extended and efforts made
to include the costs of expanding coverage of
these within national health plans, including
any health insurance entities, and to provide
the needed financing across all three disease
areas as part of universal health coverage. In
addition, developing an end-to-end process for
antiretroviral medicines for children, early infant
diagnosis and using multi-disease platforms can
improve the effectiveness of interventions.

•

Include drug and diagnostics costs increasingly in country
health financing, for example as for HIV and viral hepatitis
in Rwanda’s health insurance program and for hepatitis B
in China’s insurance programs. This also enables further
reductions as prices are aligned, for example between
hepatitis B virus and HIV.

•

Promote South-to-South support, for example Egypt’s
support for eliminating hepatitis C more widely in Africa.

•

Strengthen subnational use of unique identifiers to better
match patient numbers with drug and diagnostic stocks.

•

Facilitate drug development for new gonorrhoea
treatment and options for syphilis treatment and
availability of STI drugs and diagnostics at the primary
health care level.

There have been strong improvements in
HIV medicines with regards to antimicrobial
resistance supported by a global action plan.
Cross-cutting antimicrobial resistance actions
across HIV, STIs and TB could be strengthened.

•

Improve surveillance and monitoring of antimicrobial
resistance for HIV and STIs.

•

Improve data use to reduce loss to follow-up on life-long
HIV treatment.

•

Align actions to address antimicrobial resistance for HIV
and STIs and coordinate with cross-cutting management
of antimicrobial resistance.

6. Strengthen
joint responses to
HIV, viral hepatitis
and STIs with
TB and other key
comorbidities

There has been major progress in provision of
testing and treatment, but TB remains the major
cause of death among people living with HIV.
Programmes in many countries in sub-Saharan
Africa remain separate in terms of management,
supply chains and monitoring.

•

Review integration of HIV and TB programmes, especially
in sub-Saharan Africa, while continuing strong progress in
aligning testing and treatment.

•

Align joint monitoring approaches in terms of use of
health information system platforms such as DHIS-2,
programme reviews and ongoing data use to improve
services.

7. Integrate sexual
and reproductive
health and rights

Many countries have pioneered important
approaches in relation to key and vulnerable
populations, but progress has met significant
barriers. Renewed efforts are required to secure
sexual and reproductive rights for all.

•

Extend activities across all three disease areas and
mainstream key components in universal health care
approaches, where the tracer is often progress in key and
vulnerable populations.

•

Integrate STI prevention and care services into HIV,
adolescent health, antenatal care and sexual and
reproductive health services and primary health care.

•

Further integrate sexual and reproductive health rights
including STIs into existing programmes, including those
supported by the Global Fund and the United States
President’s Emergency Plan for AIDS Relief (PEPFAR).

•

Support national prevention programmes with strong
leadership to tackle social and structural determinants,
since many countries suggest these have not been
adequately supported at the highest level

•

Develop activities across the Triple Billion targets,
leveraging the increasing WHO emphasis on social and
structural determinants.

5. Protect against
the threat of
antimicrobial
resistance

8. Address social
and structural
determinants

The failure to achieve HIV incidence reduction
targets and STI targets highlights the need
to address social, behavioural and structural
determinants more directly in the next decade to
progress towards elimination.

Actions identified to leverage innovations and lessons from the COVID-19 response
9. Maximize the use
of differentiated
and people-centred
service delivery
options

Many of the policies have been developed,
but they gained additional impetus in
implementation in response to the COVID-19
pandemic. This momentum needs to be further
leveraged to build back a stronger response to
HIV, viral hepatitis and STIs.

•

Extend flexibility in policies, such as multimonth
dispensing of antiretroviral medicines to six months, and
require differentiated care policies to be in place.

•

Strengthen the use of person-centred data and digital
health to further implement people-centred service
delivery.

10. Strengthen
community
engagement,
community-based
service delivery
and community-led
monitoring

Community engagement has been a critical
part of the response, but communities have
increasingly taken on additional responsibilities
to integrate prevention, testing and treatment
with innovative approaches in response to the
COVID-19 pandemic.

•

Integrate community-level services to bring together
prevention, testing and treatment.

•

Develop direct, simplified service delivery that goes
beyond health facilities, using community networks and
workplaces to reach the most vulnerable populations,
adolescent girls and young women and men.
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Box 16.
Spotlight: accelerating progress within the frameworks of universal
health coverage and primary health care
The responses to HIV, viral hepatitis and STIs play an
important role in advancing the global goals of universal
health coverage and primary health care (67,68). Similarly,
increased investment in the key components of primary
health care drive progress towards disease-specific goals
and people-centred care as critically important elements
of the push for universal health coverage. With universal
health coverage as the goal, strengthening primary health
care while continuing with disease-specific approaches can
ensure optimal opportunities for people-centred services
and greater efficiency through strengthened integration.
More efforts are needed to separate ends and means;
ensuring that more integrated systems are accountable
to deliver disease-specific goals, mainly through primary
health care, to deliver on progress towards universal health
coverage. This requires greater alignment of diseasespecific and overall health system efforts at the policy,
programme, and service levels.
Universal health coverage means that all people have
access to the health services they need, when and where
they need them, without financial hardship. Effective control
of disease is therefore integral to progress towards universal
health coverage. The global health sector strategies for HIV,
viral hepatitis and STIs recognize universal health coverage
as an overarching guiding framework and contribute
towards its progressive realization; in turn, progress towards
universal health coverage enables a comprehensive
response to these diseases.
People-centred and resilient health systems that deliver
primary health care are essential to achieve universal health
coverage. In the Declaration of Astana (2018), countries and
international partners committed themselves to orienting
health systems towards primary health care for accelerated
progress on universal health coverage and the health-related
Sustainable Development Goals (67).

The global response to HIV, viral hepatitis and STIs is
anchored in these principles. Joint efforts across these
diseases are important steps towards advancing universal
health coverage and primary health care through diseasespecific action. These include strengthening cross-cutting
surveillance and information systems, deploying multidisease diagnostic technologies, strengthening self-care
and self-management approaches, addressing common
price and patent-related barriers, integrating diseasespecific financing into universal health coverage packages,
empowering communities and addressing common social
determinants of health.
For many countries, integrating primary health care across a
wide range of policies, strategies, activities and services is
likely to require substantial transformation of how healthrelated policies and actions across disease areas are given
priority, funded and implemented (67). Each country will
progress towards universal health coverage and primary
health care in accordance with local contexts and priorities.
Countries will need to assess, set priorities for, optimize
and sequence their actions as part of national health sector
planning. These processes should occur in the context of
an inclusive planning process with community participation
that includes the most vulnerable, disadvantaged and
marginalized people, and care must be taken to ensure
that greater integration does not compromise the focus on
disease-specific responses that serve these populations.

Fig. 30. Primary health care: a whole-of-society approach

Primary health care covers the range of disease prevention,
health promotion, treatment, rehabilitation and palliation care
that are needed throughout a person’s lifespan, delivered as
close as feasible to people’s everyday environment. WHO’s
vision for primary health care seeks to achieve healthy lives
and well-being for all by building people-centred, resilient
and sustainable primary health care–based health systems
that uphold the right to health, empower individuals and
communities and address the determinants of health through
multisectoral policy and action.

Source: WHO & UNICEF (69).
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3.7 WHO actions
Each of the global health sector strategies defines fasttrack actions that WHO must undertake to support
countries to accelerate progress in the fight against
HIV, viral hepatitis and STIs. This section highlights
the WHO actions for which major gaps remain and
identifies suggested steps to address these gaps.

Box 17.
Spotlight: contributing to achieving the WHO Triple Billion targets
WHO’s Triple Billion targets are an ambitious initiative to
achieve measurable impact on the health of billions of people
worldwide by 2023 such that:

Progress towards eliminating HIV, viral hepatitis and STIs
as public health threats contributes tangible results towards
achieving the Triple Billion targets.

• one billion more people benefit from universal health
coverage;

• one billion more people enjoy better health and wellbeing.

• The first billion. All three disease strategies share a
vision to deliver the three dimensions of universal health
coverage – improving the availability and quality of
essential health services, ensuring equitable access
to services in relation to need and reducing costs and
providing financial protection for those who need the
services.

These targets provide the foundation of WHO’s Thirteenth
General Programme of Work and are an integral part of WHO’s
results framework to measure and improve how WHO’s
affects health at the country level.

• The second billion. With their contributions to building
health system capacity and resilience, HIV, viral hepatitis
and STI programmes also contribute to public health
emergency preparedness, detection and response.

• one billion more people are better protected from health
emergencies; and

• The third billion. By addressing structural barriers
and promoting gender-responsive programming, they
contribute to better health and well-being for all.
Fig. 31. Regular reviews use disease data to identify actions to contribute to the WHO Triple Billion Goals

Identify priority countries
Identify
priority
countries

Prioritize impactful actions

Building
back better

Source: WHO, 2021
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Reﬂect key actions in the policy
dialogue, program budget and
Covid-19 recovery plans
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Table 11. WHO action with gaps in 2020 and steps to address these by 2030
Global health
sector strategy

WHO action with significant gap in
2020

Suggested steps to address the gap by 2030

HIV

Advocate for and support the expansion of
new prevention technologies.

Include new approaches for prevention, including social and
structural determinants, in the next phase of the global health
sector strategies with reference to the UNAIDS Global AIDS Strategy
2016–2026 (70) and its three strategic priorities: maximize equitable
and equal access to HIV services and solutions; break down barriers
to achieving HIV outcomes; and fully resource and sustain efficient
HIV responses and integrate them into systems for health, social
protection, humanitarian settings and pandemic responses.

Provide guidance on combination HIV
prevention.

Provide implementation guidance on how to balance funding for
various prevention priorities.

Support countries with tools and technical
assistance.

Strengthen partner technical support and support from WHO
regional offices.

Support countries in fully implementing
WHO’s injection safety policy and global
campaign.

Highlight injection safety in the next phase of the global health
sector strategies.

Provide advocacy and technical support to
countries to mobilize commitment to harm
reduction.

Address barriers to harm reduction as a cross-cutting priority in the
next phase of the global health sector strategies.

Provide guidance on quality assurance and
quality improvement systems.

Assess approaches to improve quality assurance and improvement
in countries.

Provide policy and technical guidance aimed
at building a competent workforce.

Develop guidance on differentiated human resources support for
hepatitis services.

Provide technical support to countries to
forecast the need for essential hepatitis
commodities.

Initiate forecasting for hepatitis C commodities in the 2021
forecasting meeting for drug and diagnostics stakeholders and
partners.

Support regulatory authorities in premarket assessment and registration of new
hepatitis medicines and diagnostics, with
post-market surveillance.

Strengthen post market surveillance to support regulatory
authorities.

Assess the quality and performance of
commercially available hepatitis diagnostics.

Consider in the next phase of the global health sector strategies.

Ensure linkage of some components of STI
surveillance to existing mechanisms.

Develop a new monitoring and evaluation and surveillance
framework for STIs.

Provide technical support to countries with
STI programmes.

Strengthen joint STI and HIV country support.

Update and disseminate guidance for
targeted populations on STI vulnerability and
risk-reduction interventions.

Include stronger focus on key populations in the next phase of the
global health sector strategies and generate better data.

Strengthen efforts to ensure that highquality diagnostics for STIs are accessible
and available.

Implement STI diagnosis, screening strategies for key population
and vulnerable populations such as adolescents, pregnant women
and other bridge populations, including men; and facilitate the
development of low-cost point-of-care tests for STIs.

Develop and support public–private
partnerships to catalyse the development of
new technologies.

Develop and support public–private partnerships to catalyse the
development of new technologies.

Viral hepatitis

STIs
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4
Progress by WHO region
4.1 African Region
The African Region leads the way
in HIV testing and treatment
and has the opportunity over
the next decade to extend this
to addressing hepatitis B and C
and syphilis transmission from
mother to child

Table 12. African Region: data at a glance, 2019–2020
Disease area

Indicator

Numbers

HIV (2020)

People acquiring HIV

880 000
[590 000–1 300 000]

People dying from HIV-related causes

460 000
[320 000–680 000]

Viral hepatitis
(2019)

Incident cases of hepatitis B infection

990 000
[660 000–1 600 000]

Incident cases of hepatitis C infection

210 000
[150 000–370 000]

People dying from hepatitis B infection

80 000
[47 000–110 000]

People dying from hepatitis C infection

45 000
[23 000–72 000]

STIs (2020)

Incident cases of gonorrhoea

19 200 000
[10 000 000–32 200 000]

Incident cases of syphilis

2 200 000
[1 300 000–3 100 000]
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Table 13. African Region: highlights and priority action

HIV

Viral hepatitis

Data availability and quality have improved
greatly – all countries are reporting on key
HIV cascade indicators; HIV programme
data are integrated into the health
management information system; and key
population size estimates are improving.
Of 47 countries in the region, 44 have size
estimates for sex workers, 40 for gay men
and other men who have sex with men,
20 for people who inject drugs and 7 for
transgender people.

Twenty-eight countries had national
hepatitis strategic plans in 2018.

In 2020, 76% [60–92%] of the people
living with HIV had access to HIV
treatment, and five countries (Botswana,
Eswatini, Malawi, Rwanda and Uganda)
had achieved the 90–90–90 targets.

Egypt has initiated support for
planning towards eliminating viral
hepatitis in sub-Saharan African
countries, a leading example of
South-to-South support.

Differentiated service delivery is improving
uptake and quality – 42 countries
implementing multimonth dispensing of
antiretroviral drugs for 3–6 months.

Joint approaches to viral hepatitis
and HIV coinfection provide
opportunities, given the reductions
in prices for hepatitis B and C
treatment.

Access to diagnosis and treatment
is still limited.
Hepatitis reporting has improved
significantly in the Region since
the mid-term report but major gaps
remain.

Access to voluntary medical male
circumcision is expanding – 27 million
adolescent boys and men in 15 countries
reached in eastern and southern
Africa, achieving 60% of the target and
preventing 340 000 people from acquiring
HIV by 2019.

Sexually transmitted infections
Countries in the Region with high
HIV prevalence also face a high
prevalence of HPV infection and
cervical cancer incidence and
mortality, but many countries have
not yet introduced HPV vaccination
for girls, and the integration of
cervical cancer screening with HIV
services needs to be strengthened.
There has been progress in dual
testing for HIV and syphilis and
approaches for eliminating the
mother-to-child transmission of
the two diseases.
Very high levels of STIs and
HIV incidence among women in
antenatal care have shown the
need for stronger approaches to
integrate prevention and treatment
and to tackle similar social and
sexual determinants.
To strengthen STI and HIV
prevention surveillance, joint
approaches, including STI
prevalence surveys, are required.

PrEP services are scaling up– of 47
countries in the Region, 22 provide PrEP
to adolescent girls and young women,
sex workers, gay men and other men who
have sex with men, transgender people,
people who inject drugs and/or prisoners.

Three countries have achieved elimination of mother-to-child transmission of HIV and/or syphilis;
11 are on the path to elimination.

PRIORITY
ACTIONS
• Invest in integrated data systems and streamline the
governance of data reviews and use.
• Continue to scale up differentiated service delivery,
leveraging the innovations from the COVID-19 response.
• Intensify efforts to reach men at higher risk of HIV
infection.

• Advance integrated people-centred health services
across diseases, with greater decentralization, task
sharing and community engagement as part of universal
health coverage.
• Continue to advocate for domestic investment and
innovative financing mechanisms; especially to address
the chronic funding gaps for viral hepatitis and STIs.
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Box 18.
Engaging communities in voluntary medical male circumcision in
Malawi and the United Republic of Tanzania
Voluntary medical male circumcision is a critical component
of a combination prevention strategy in settings with
high HIV prevalence, in particular in eastern and southern
Africa. Voluntary medical male circumcision is also a
critical strategy to link adolescent boys and men to health
services and increase service uptake. Many countries are
implementing strategies to generate demand and address
barriers to scaling up voluntary medical male circumcision
among adolescent boys and men.
In a high-burden district of Malawi, satisfied prior clients
of voluntary medical male circumcision were engaged as
community mobilizers to expand demand creation. They
were provided with a bicycle for transport, identification
cards and branded T-shirts and equipped with training and
job aids to address common myths and misconceptions
regarding voluntary medical male circumcision among men
in their communities. The uptake of voluntary medical male
circumcision in the district increased from 32% in 2017 to
71% in 2018, the highest level in five years (71).
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In the United Republic of Tanzania, after data analysis
revealed that male circumcision rates among men
25–29 years old were low in priority districts, an initiative
sought to integrate voluntary medical male circumcision
within existing community-based mobile HIV testing.
Adjacent tents offering HIV testing and voluntary medical
male circumcision were set up near hotspots, and peer
educators linked the clients of HIV testing to voluntary
medical male circumcision. The initiative helped to reduce
waiting times and travel distance and provided more
privacy compared with facility-based voluntary medical
male circumcision. Older men represented 38% of voluntary
medical male circumcision clients reached through mobile
teams versus 11% of clients reached through facility-based
modalities (72).

4. Progress by WHO region

4.2 Region of the Americas
The Region of the Americas has led the
approaches to dual elimination of mother-tochild transmission of HIV and syphilis and
delivering the HIV service cascade for key
populations. Over the next decade, they will
need to fill the gaps in the service cascade for
HIV, viral hepatitis and STIs

Table 14. Region of the Americas: data at a glance, 2019–2020
Disease area

Indicator

Numbers

HIV (2020)

People acquiring HIV

150 000
[110 000–210 000]

People dying from HIV-related causes

45 000
[30 000–63 000]

Viral hepatitis
(2019)

Incident cases of hepatitis B infection

10 000
[5 100–26 000]

Incident cases of hepatitis C infection

67 000
[63 000–73 000]

People dying from hepatitis B infection

15 000
[8 500–23 000]

People dying from hepatitis C infection

31 000
[19 000–84 000]

STIs (2020)

Incident cases of gonorrhoea

9 800 000
[5 300 000–17 000 000]

Incident cases of syphilis

2 500 000
[1 500 000–3 500 000]
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Table 15. Region of the Americas: highlights and priority actions

HIV

Viral hepatitis

Sexually transmitted infections

The number of people acquiring HIV
declined between 2010 and 2020
in the WHO Region of the Americas
by 6%, whereas in the Caribbean it
declined by 28%, but plateaued in
Latin America.

Previously adopted preventive
interventions, including vaccination
and blood safety, have enabled
the regional elimination of early
childhood transmission of hepatitis
B (hepatitis B surface antigen <0.1%
among children five years-old).

Key populations have a high
burden of syphilis, and syphilis is
increasing among pregnant women
in some countries. Congenital
syphilis cases are underdiagnosed
and underreported.

Coverage of HIV treatment services
is increasing (67%), and most
countries have adopted “treat all”
policies.
Coverage of HIV prevention services
is uneven. About 64% of gay men
and other men who have sex with
men reported using a condom at
last anal sex, but the number is less
than 50% in nine countries. Roll-out
of PrEP has been slow.
Nine countries have developed key
population prevention cascades
and implemented policy and
programmatic changes based on
their findings.

A total of 23 countries had national
hepatitis strategic plans in 2020
versus 10 in 2015.
However, access to diagnosis
and treatment is still limited, and
few people living with hepatitis B
and hepatitis C virus have been
diagnosed.
High prices of commodities and
complex patent protection schemes
that limit access to generics
continue to pose barriers.

HIV self-testing is expanding, with
national policies adopted in five
countries and being developed in 15
countries.

Eight countries have achieved elimination of mother-to-child transmission of HIV and/or syphilis.

PRIORITY
ACTIONS
• Expand integrated testing and treatment services, such
as the joint elimination of mother-to-child transmission
of HIV and syphilis as part of maternal and child health,
common platforms for HIV and STI testing and mental
health.
• Facilitate access to commodities by taking a joint
approach to addressing market and patent barriers.
• Expand the roll-out of differentiated approaches for HIV,
including multimonth dispensing of medicines, expanded
role of lay providers and use of telemedicine.

• Improve surveillance and information systems, especially
on viral hepatitis and STIs.
• Strengthen surveillance of antimicrobial resistance for
N. gonorrhoeae and align treatment guidelines with local
susceptibility patterns.

4. Progress by WHO region

Box 19.
Community-led solutions to maintain HIV and STI services during the
COVID-19 pandemic in Argentina and Guatemala
In Argentina, Fundación Huésped provides communitybased services related to HIV and AIDS, viral hepatitis,
STIs and other sexual and reproductive health services to
populations in need, especially key populations. During the
COVID-19 pandemic, Fundación Huésped adapted rapidly
to the COVID-19 context by expanding the use of telehealth
and providing all staff with the necessary equipment for
remote work. The only required physical visit to the clinic
was for sample collection for testing. The expanded use
of telephone and virtual consultations enabled Fundación
Huésped to reach a greater number of people from a wider
geographical area. Between March and November 2019, the
15 staff members of Fundación Huésped provided services
to 1500 clients per month versus 330 clients per month
during the same period in the previous year.

Other community-based organizations in the Region adopted
similar approaches. Community-based clinic Colectivo
Amigos Contra el SIDA in Guatemala City, one of the largest
HIV and STI community clinics in Central America for gay
men and other men who have sex with men, introduced HIV
self-testing to maintain sexual health services for gay men
and other men who have sex with men. Clients could request
test kits through the clinic’s website and receive them by
mail. The clinic also adopted multimonth dispensing of
PrEP and other essential supplies. As a result, not only were
services maintained within the city but men outside the city
could also access services with online support.

© John Rae
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4.3 South-East Asia Region
The South-East Asia Region has some of the
world’s leading programmes for key populations
and community-based responses. Three countries
in the Region have been validated for EMTCT of
HIV and syphilis and four countries have been
certified to have achieved hepatitis B control
through immunization. Progress in the response
to HIV and STIs has nevertheless plateaued.
Financing for HIV, viral hepatitis and STIs needs
to be sustained and expanded towards universal
health coverage.

Table 16. South-East Asia Region: data at a glance, 2019–2020
Disease area

Indicator

Numbers

HIV (2020)

People acquiring HIV

100 000
[71 000–130 000]

People dying from HIV-related causes

82 000
[55 000–130 000]

Viral hepatitis
(2019)

Incident cases of hepatitis B infection

260 000
[180 000–590 000]

Incident cases of hepatitis C infection

230 000
[200 000–430 000]

People dying from hepatitis B infection

180 000
[140 000–300 000]

People dying from hepatitis C infection

38 000
[37 000–130 000]

STIs (2020)

Incident cases of gonorrhoea

21 100 000
[7 600 000–45 000 000]

Incident cases of syphilis

350 000
[110 000–600 000]
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Table 17. Regional highlights and priority actions

HIV

Viral hepatitis

Sexually transmitted infections

The number of people acquiring HIV
declined by 29% and the number
of people dying from AIDS-related
causes decreased by 48% between
2015 and 2020. However, progress
has plateaued, and members of key
populations and their partners are
acquiring HIV.

Eight countries in the Region have
national hepatitis strategic plans.

There are several best practices
in STI control in the Region
at subnational levels, even in
countries with uneven overall
implementation.

HIV treatment coverage increased
from 37% in 2015 to 61% in 2020, but
the region is off-track for achieving
the 2020 targets.
The uptake of HIV self-testing and
PrEP has been slow; and progress
in addressing comorbidities such as
HIV and TB has been insufficient.
In response to COVID-19, several
countries applied differentiated
and innovative approaches such
as increased use of telemedicine
and multimonth dispensing and
take-home doses of HIV treatment
and opioid substitution therapy and
engaging communities as effective
partners in service delivery.

There have been strong gains in
coverage of hepatitis B vaccination,
and four countries in the Region
have achieved 2020 control
targets through immunization. The
prevalence of hepatitis B infection
has declined significantly.
There has been slow progress
in scaling up access to hepatitis
diagnosis and treatment, and
mortality has not yet declined.
Funding for viral hepatitis remains
inadequate, and the prices of
commodities vary across countries.

Trends in curable STIs are declining
overall, except syphilis in a couple
of instances. STI surveillance in the
Region remains weak.
Eight countries in the Region have
an official national STI strategy;
among these, it is integrated with
the national HIV strategy in five
countries. However, there has been
a relative lack of commitment and
giving priority to STIs in the Region
overall.
Screening for STIs among key
populations and in antenatal care
settings is low, with many missed
opportunities.

Three countries – Maldives, Sri Lanka and Thailand – have been validated as achieving elimination of mother-to-child
transmission of HIV and syphilis. Access to harm reduction in the Region is low.

PRIORITY
ACTIONS
• Enhance the coverage of prevention and testing services
with linkage to treatment.

• Advance a triple elimination framework to end mother-tochild transmission of HIV, hepatitis B and syphilis.

• Reinvigorate programmes with increased focus on key
populations and people at higher risk.

• Utilize price advantages fully, since the costs of health
commodities vary greatly in the Region.

• Address barriers to accessing services, including stigma
and discrimination.

• Strengthen surveillance and disease burden estimates
with better collection and utilization of data.

• Give priority to hepatitis, HIV and STI within universal
health coverage and with improved financing and
investment cases.

• Maximize the potential of decentralized approaches,
including the private sector, to achieve universal health
coverage.
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Box 20.
Community-led interventions for improving health outcomes
across the Region
Several community-led initiatives are demonstrating
their potential to improve health outcomes for affected
populations and provide valuable lessons for wider scale-up
within the Region and beyond. For example, a communitybased organization for female, male and transgender sex
workers in southern India has demonstrated improvements
in coverage, utilization and outcomes of HIV and STI
services with a shift from implementation with sex workers
as active partners towards programmes run by them (73).
In a participatory training initiative in Thailand, people living
with HIV and members of key populations were co-trainers
alongside health facility staff (74). This initiative significantly
reduced stigma and discrimination among health-care
workers towards people living with HIV and key populations.
Experiences from Indonesia among gay men and other
men who have sex with men highlight the importance of
social support from buddies in HIV treatment initiation and
adherence (75).

© John Rae

Experiences across the Region have also demonstrated
how interventions that place communities at the centre
can achieve strong health outcomes (76). In Nepal, a
community-based intervention leveraged existing sites
providing opioid substitution therapy for people who inject
drugs and provided hepatitis C virus screening and linkage
to treatment. The role of communities has also been well
recognized in other areas such as in advocacy for access
to medicines for hepatitis C (77–79). During the COVID-19
pandemic, community-based organizations played critical
roles in providing immediate, short-term mitigation efforts
(80). Nevertheless, these experiences also underscore the
need for reconsidering social protection arrangements,
addressing structural barriers and providing support
to communities to ensure sustained ownership and
involvement (81).

4. Progress by WHO region

4.4 European Region
Gaps in testing and treatment for HIV, viral
hepatitis and STIs need to be filled rapidly in
the European Region. There have been major
advances in hepatitis programme planning, but
the estimated number of people acquiring HIV
has been increasing.

Table 18. European Region: data at a glance, 2019–2020
Disease area

Indicator

Numbers

HIV (2020)

People acquiring HIV

170 000
[140 000–200 000]

People dying from HIV-related causes

40 000
[31 000–51 000]

Viral hepatitis
(2019)

Incident cases of hepatitis B infection

19 000
[9 400–38 000]

Incident cases of hepatitis C infection

300 000
[240 000–320 000]

People dying from hepatitis B infection

43 000
[34 000–51 000]

People dying from hepatitis C infection

64 000
[39 000–72 000]

STIs (2020)

Incident cases of gonorrhoea

3 800 000
[1 500 000–7 300 000]

Incident cases of syphilis

240 000
[130 000–340 000]
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Table 19. European Region: highlights and priority actions

HIV

Viral hepatitis

Sexually transmitted infections

The number of people acquiring HIV
has been increasing in the Region.

A total of 33 countries in the Region
have national hepatitis strategic
plans.

A total of 38 countries have policies
and/or guidelines on STI diagnosis
and treatment.

The scale up of diagnostics and
treatment has been slow.

Non–European Union countries
have limited data on STIs.

Service coverage is improving –
77% of people living with HIV know
their HIV status, 83% of those who
know their HIV-positive status
receive antiretroviral therapy and
94% of those on treatment have
suppressed viral loads; but the 2020
targets have not been reached.

There are major gaps in hepatitis
data.

The “treat all” policy has been
implemented in all countries. The
transition to dolutegravir has been
slow due to the high cost in some
middle-income countries.
The scale-up of PrEP has been slow.

• Harm reduction continues to be a low priority in some countries.
• The costs of medicines and diagnostics remain high in middle-income countries that face patent-related barriers.

PRIORITY
ACTIONS
• Catch-up plan for COVID-19-related slowdown in progress
on key interventions.

• Scale up early antiretroviral therapy provision with
optimized regimens and improved quality of care.

• Tailor prevention to key populations, with an integrated
people-centred approach across disease areas.

• Strengthen hepatitis surveillance and monitoring
and evaluation to better understand the situation and
progress.

• Take an integrated approach to addressing harm
reduction and mental health for key populations.
• Use PrEP as an opportunity for better STI screening and
treatment in key populations.
• Strengthen civil society involvement in the regional
response.
• Decentralize and simplify HIV testing.

• Increase the number of countries with funded national
plans for hepatitis.
• Simplify hepatitis testing strategies and treatment and
improve access to treatment.
• Strengthen STI surveillance.

4. Progress by WHO region

Box 21.
Expanding access to hepatitis C treatment in Belarus through state
funding and local production
An estimated 100 000 people live with chronic hepatitis C
in Belarus. Most new cases occur among the working-age
population, and liver cirrhosis caused by chronic hepatitis
C is the most common indication for liver transplantation
in Belarus.
Since 2018, the Government of Belarus has funded directacting antiviral drugs for people with chronic hepatitis
C infection across the country. Belarus also updated its
national protocol for diagnosis, treatment and care for
people with chronic hepatitis C and developed a 10-year
plan for expanding access to hepatitis C treatment from
2019 to 2028. In 2019, 6000 courses of the pangenotypic
regimens of sofosbuvir and daclatasvir were procured
through the state budget and distributed to health
facilities. Among 6074 people treated in 2018–2019 with
known treatment outcomes, 6062 (99.8%) had successful
treatment outcomes.

With a strong commitment to ensure the sustainability of
state-funded hepatitis-related activities, the Government of
Belarus also established local production of generic directacting antiviral drugs. As of 1 September 2018, the cost of a
12-week treatment regimen was about US$ 706, lower than
some other countries in the Region. The Ministry of Health
continues to work to further reduce costs in cooperation
with the pharmaceutical industry, representatives of
patient organizations, infectious diseases specialists and
international partners. In November 2018, Belarus hosted
the Eastern Europe and Central Asia Second Regional
Consultation on Expanding Access to Affordable and Quality
Assured Medicines and Diagnostic Technologies to make
continued use of the best global and regional practices and
tools to ensure the quality, safety and efficacy of essential
HIV, TB and hepatitis C medicines and diagnostics and to
reduce their prices.
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4.5 Eastern Mediterranean Region
The Eastern Mediterranean Region leads the
way in scaling up access to hepatitis C testing
and treatment, and some countries have an
opportunity to move towards elimination. The
impact of these population-based approaches
needs to be expanded and transferred to
hepatitis B, STI and HIV services.

Table 20. Eastern Mediterranean Region: data at a glance, 2019–2020
Disease area

Indicator

Numbers

HIV (2020)

People acquiring HIV

41 000
[35 000–60 000]

People dying from HIV-related causes

17 000
[14 000–24 000]

Viral hepatitis
(2019)

Incident cases of hepatitis B infection

100 000
[79 000–140 000]

Incident cases of hepatitis C infection

470 000
[240 000–520 000]

People dying from hepatitis B infection

33 000
[26 000–60 000]

People dying from hepatitis C infection

31 000
[31 000–74 000]

STIs (2020)

Incident cases of gonorrhoea

5 300 000
[1 900 000–11 300 000]

Incident cases of syphilis

640 000
[240 000–1 000 000]
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Table 21. Eastern Mediterranean Region: highlights and priority actions

HIV

Viral hepatitis

Sexually transmitted infections

Access to HIV testing and treatment
services is improving, yet coverage
remains low. Only 40% of people
living with HIV know their HIV
status.

Strategic information systems for
hepatitis data are slowly improving,
and two countries have conducted
serological surveys.

There is a limited focus on STIs in
the Region.

Some countries are expanding
client-centred approaches such as
HIV self-testing and PrEP, to expand
outreach to key populations.
Linkages to care and retention are a
challenge, and a search-and-rescue
initiative is being implemented in
countries such as Pakistan and
Sudan to identify people living with
HIV who may be lost to follow-up
and relink them to care.
HIV services for refugees and other
displaced people are expanding with
support from international partners.
The availability and quality of data
are improving with surveys and
cascade analyses in countries such
as Lebanon Morocco, Pakistan
and Sudan; however, data systems
remain fragmented and weak.

There has been strong momentum
and progress with major initiatives in
champion countries such as Egypt
and Pakistan; however, programmes
in most countries remain weak with
limited funding.

Some countries such as Egypt and
Lebanon have conducted surveys
on STIs among subpopulations,
but overall data are lacking to
accurately describe the burden
of STIs in the Region, and STI
surveillance systems are weak.

Coverage of hepatitis B virus vaccine
has increased to exceed 80% for the
third dose, but birth dose coverage
is low.
Diagnosis and treatment of hepatitis
B and C infection is low.
Many countries have achieved
reductions in the price of directacting antiviral drugs for hepatitis C
infection through price negotiations
and local manufacturing.

There has been progress in harm reduction, with favourable policies adopted in Egypt and Pakistan, but overall coverage of
harm reduction among people who inject drugs in the Region remains very low.

PRIORITY
ACTIONS

• Expand the use of people-centred and differentiated
service delivery models and targeted interventions for
prevention, diagnosis and treatment for key populations.
• Expand access to hepatitis diagnosis and treatment,
including with a focus on microelimination in high-burden
populations and continue to pursue price reduction
strategies and public health approaches for scale-up.
• Renew the focus on STIs through greater integration with
HIV and other health programme areas and efforts to
mobilize resources.

• Promote domestic funding and mobilize catalytic crosscutting funding.
• Make joint efforts to strengthen strategic information
for HIV, viral hepatitis and STIs as part of broader
health management information system strengthening,
including with support for electronic data collection and
promoting data use through improved analytics and
visualization dashboards.
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Box 22.
Public health scale-up of
hepatitis C diagnosis and
treatment in Egypt

Box 23.
Microelimination of viral
hepatitis in a high-burden
district in Pakistan

Egypt is one of the countries with the largest burden of
hepatitis C infection in the world. It has made significant
advances since 2018 towards eliminating hepatitis C,
supported by strong government commitment, local
generic manufacturing and price reductions obtained
through negotiations with manufacturers. During
2017–2018, Egypt conducted a massive countrywide
effort to screen the entire population aged 18 years and
older and provide treatment free of charge to everyone
with infection. Nearly 60 million people had been tested
by late 2019, and 4 million had started treatment. This
constitutes one of the largest public health efforts to
date towards eliminating hepatitis C in low- and middleincome countries worldwide. Egypt now plans to support
countries in the African Region in their scale-up efforts.

In the Punjab province in Pakistan, the Hepatitis Control
Program implemented a demonstration microelimination
project in the high-prevalence district of Nankana
Sahib. Within this district, subarea Panwan with a
total population of 29 500 people, concentrated in five
villages, was selected for this initiative, with the aim of
testing 95% of the population 12–80 years old. During
a three-week pretest phase in 2019, health education
sessions were conducted at the community level, 96% of
the target population was screened for hepatitis B and
C virus and people diagnosed were linked to treatment.
The efforts were backed by strong political commitment
and local ownership. The experience provides lessons
for pursuing hepatitis microelimination efforts in other
geographical areas of Pakistan and in other countries.
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4.6 Western Pacific Region
The Western Pacific Region has made major
progress in expanding access to services for
people with hepatitis B and C virus infection,
largely from domestic funding and substantial
reductions of drug prices. The responses to viral
hepatitis, HIV and STIs have opportunities in
national financing for universal health coverage.

Table 22. Western Pacific Region: data at a glance, 2019–2020
Disease area

Indicator

Numbers

HIV (2020)

People acquiring HIV

120 000
[78 000–150 000]

People dying from HIV-related causes

41 000
[24 000–63 000]

Viral hepatitis
(2019)

Incident cases of hepatitis B infection

140 000
[96 000–210 000]

Incident cases of hepatitis C infection

230 000
[220 000–260 000]

People dying from hepatitis B infection

470 000
[200 000–490 000]

People dying from hepatitis C infection

77 000
[77 000–140 000]

STIs (2020)

Incident cases of gonorrhoea

23 200 000
[11 200 000–40 700 000]

Incident cases of syphilis

1 100 000
[620 000–1 600 000]
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Table 23. Western Pacific Region: highlights and priority actions

HIV

Viral hepatitis

Sexually transmitted infections

Several innovative interventions
have been introduced to expand
service outreach, driven in part by
the COVID-19 pandemic, including
community-led interventions using
online platforms to reach people
with information and increase
access to services.

National action plans are in place in
20 countries, strategic information
action plans in seven countries and
investment cases, including disease
burden and economic analysis, have
been developed in 13 countries.

Treatment guidelines have been
revised in 21 countries to include
WHO recommendations for
dual treatment of people with
gonorrhoea.

New interventions, including PrEP,
HIV self-test and lay-provider
testing, have been introduced in
seven countries.

The coverage of hepatitis services is
expanding through domestic funding
in 19 countries.

The fixed-dose combination of
tenofovir disoproxil fumarate +
lamivudine + dolutegravir has been
introduced in six priority countries.

Drug prices have been reduced
substantially, and hepatitis
medicines have been included in
national health insurance in China
and Mongolia. Malaysia applied
TRIPS flexibilities to expand access
to hepatitis C medicines.

Needle and syringe distribution
targets have been met in Australia
and Cambodia.

Hepatitis services are being scaled
up at primary health care level in 10
countries.

Disease burden estimates were
modelled in five countries, but the
overall availability and quality of
STI data are weak.
Countries such as Cambodia and
the Philippines are implementing
initiatives to combat antimicrobial
resistance.

Public–private partnership service
delivery models are being rolled out
in Papua New Guinea.

One country has achieved elimination of mother-to-child transmission of HIV and syphilis.

PRIORITY
ACTIONS

• Maximize opportunities for integrating services based
on local epidemiology and context, including across
reproductive health services, HIV, viral hepatitis and
TB services and noncommunicable diseases, and
decentralize integrated services to the primary health
care level.
• Pursue high-level advocacy for domestic financing and
multisectoral collaboration, including the private sector,
and promote an integrated health financing approach.

• Promote the active involvement of communities for
advocacy, stigma and discrimination reduction and
service delivery.
• Integrate strategic information into existing systems and
simplify data collection to improve quality and increase
use.

4. Progress by WHO region

Box 24.
Unblocking the barrier of high drug prices to achieve universal coverage
for hepatitis medicines in China
In 2015, access to treatment was limited for China’s
estimated 96 million people living with hepatitis B and C
virus. Tenofovir disoproxil fumarate to treat hepatitis B
virus was under patent protection and cost US$ 2950 per
year. The price of generic entecavir was US$ 1300–1400
per year, and the originator price was US$ 1600–2000 per
year. The price of hepatitis C medicines was US$ 10 000 for
a cure. These medicines were not universally and equitably
reimbursed through health insurance throughout the
country, so most people were paying out of pocket.
To address this major barrier, WHO supported the
government and stakeholders in performing economic
analysis and health technology assessment of new
medicines and facilitated round-table discussions on
intellectual property rights and sharing of drug price

information from other countries. The National Health
Commission was able to use this information to successfully
negotiate a price reduction for tenofovir disoproxil fumarate
to US$ 960 per year in 2016, and the prices of entecavir were
reduced accordingly. The government continued its pursuit
of universal coverage in successive years by including
hepatitis B and C medicines in the national reimbursement
drug list and centrally pooled procurement. In early 2021,
hepatitis C treatment cost US$ 1500–2000 for a cure, a
reduction of 20%, and for hepatitis B virus costs US$ 10
per year, a reduction by an astounding factor of 300. The
reduction in prices enabled these medicines to be covered
in the national health insurance, providing affordable care to
many more people living with chronic hepatitis.
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5
Looking ahead to 2030
Despite major progress over the past decade, the 2020 targets
were off-track in major areas even before the COVID-19
pandemic. The ambition of the next decade to eliminate HIV,
viral hepatitis and STIs as public health threats by 2030 is
enormous yet feasible.

The pandemic has exposed the deep social, economic and
gender inequalities that make some people more vulnerable to
disease and determine their health outcomes. The population
groups most severely affected by HIV, viral hepatitis and
STIs also encounter the greatest stigma, discrimination and
marginalization and face difficulty in accessing the services they
need. In some ways, they are tracer populations for the progress
of inclusive and innovative universal health coverage that
reaches beyond health facilities into communities.
The massive expansion in service delivery that will be required
over the next decade must be matched by efforts to tackle
the structural barriers that undermine the response. To get
close to elimination, all countries must continue to go beyond
heath service delivery to address the social and structural
determinants of health and equitably serve the populations
most severely affected and at higher risk. Communities must be
fully resourced to play their role in reaching those who are hard
to reach, delivering services, advocating for change and holding
decision-makers accountable. People-centred health services
means tailoring services to people but also involving them in a
new partnership in their delivery.
Shifting towards elimination was always going to require a leap
forward in our approaches. The lessons from the COVID-19
response provide a historical opportunity to foster greater
solidarity and innovation in the response to infectious diseases
over the next decade. Disease-specific responses and the goals
of primary health care, universal health coverage and health
security are mutually reinforcing and need to be advanced
through an integrated health systems approach. Closer links
between HIV, viral hepatitis and STI services with related

communicable and noncommunicable disease services can
make intervention more efficient and improve their coverage
and quality. Joint efforts to strengthen clinical and laboratory
platforms, logistics management, information systems and
human resource planning offer many opportunities to jointly
strengthen health systems that will be resilient, adaptable and
equitable, including to address future pandemics.
Achieving this requires learning from the fragility and solidarity
of global health experienced with COVID-19 and ensuring
renewed political commitment and sustainable financing to
take the response to HIV, viral hepatitis and STIs to the next
level. Such a response must be anchored in the principles of
human rights and social justice. By acting decisively now, we
can emerge stronger from the challenge of COVID-19 and use
this momentum to reach the goals of the 2030 Agenda for
Sustainable Development.

Eliminating HIV, viral hepatitis
and STIs as public health threats
will require collective efforts
towards universal health coverage
and global health security,
leveraging the resilience and
innovation seen in the global
response to COVID-19.

5. Looking ahead to 2030

Box 25.
Developing global health sector strategies for HIV, viral hepatitis
and STIs for 2022–2030
As the global health sector strategies 2016–2021 reach
the end of their implementation period, WHO will lead a
consultative process to develop the next phase of the
strategies to guide action towards eliminating these
infections as public health threats by 2030. Taking into
account the progress achieved to date and remaining gaps
in achieving 2030 goals, the process will define the way
forward for country and WHO action over the next decade.
Although many of the core public health interventions
and target populations of the strategies remain relevant,
there have been contextual shifts that must be considered
in the next phase. The COVID-19 pandemic has strongly
affected public health worldwide, drawing attention to the
risks of unprepared health systems, exposing the social
determinants of health and spurring innovations. The new
strategies will ensure that the global response to HIV, viral
hepatitis and STIs responds to these shifts to deliver health
for all.
The new strategies will also take into account
epidemiological and technological developments since 2016,
such as updated estimates of the burden of disease, the
availability of new diagnostics and medicines and advances
in service delivery approaches. They will also consider
the evolving global landscape of shifts in domestic and

donor funding and align with political commitments such
as those on primary health care (the 2018 Declaration of
Astana (67)) and universal health coverage (United Nations
General Assembly Resolution A/RES/74/2 (68)). They will
promote synergy with other global strategy processes such
as the UNAIDS post-2021 global AIDS strategy and the
new strategy under development for the Global Fund. To
strengthen accountability, the strategies will include interim
targets for 2025 as milestones towards 2030 goals.
WHO’s technical leadership, normative guidance and country
support remain critical for Member States and partners to
implement the next phase. The new strategies will ensure
that WHO remains well positioned to provide leadership
on achieving the 2030 targets for HIV, viral hepatitis and
STIs as part of the broader goals of primary health care and
universal health coverage.
The strategy development process will include consultations
with Member States, partners, civil society, communities
and other stakeholders and public online consultations in
the official WHO languages. These consultations will be held
during 2021, with a view to presenting the final strategies for
consideration by the World Health Assembly in May 2022.
The current strategies will remain active until that time.
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